



**HEALTH & POPULATION  
DEPARTMENT**



# **BIDDING DOCUMENT**

(FRAMEWORK CONTRACT FOR THE PROCUREMENT OF  
DRUGS/MEDICINES)

(FINANCIAL YEAR 2026-27)

**Bid reference No. PC-01/Drugs/Medicines/26-27**

**Directorate General Health Services, Punjab  
HEALTH & POPULATION DEPARTMENT  
GOVERNMENT OF THE PUNJAB**

# CONTENTS

Tender Data Sheet

## **SECTION 1**

Invitation to Tender

Letter of Invitation

## **SECTION II**

Instructions to Bidders

1. Scope of Bid
2. Source of Funds.
3. Eligible Bidders
4. Corruption and Fraud & Mechanism of Blacklisting
5. Eligible Goods and Services
6. Cost of Bidding.
7. Bidding for Selective Items. The Bidding Procedure
8. The Governing Rules
9. Applicable Bidding Procedure. The Bidding Documents
10. Contents of the Bidding Documents
11. Clarification(s) on Bidding Documents
12. Amendment(s) to the Bidding Documents. Preparation of Bids
13. Language of Bids
14. Documents comprising the Bids.
15. Bid Price.
16. Bid Currencies.
17. Samples.
18. Documentation on Eligibility of Bidders.
19. Documentation on Eligibility of Goods
20. Bid Security
21. Bid Validity
22. Format and Signing of Bids. Submission of Bids
23. Sealing and Marking of Bids
24. Deadline for Submission of Bids
25. Late Bids
26. Withdrawal of Bids Opening and Evaluation of Bids
27. Opening of Bids by the Procuring Agency
28. Clarification of Bids
29. Preliminary Examination
30. Evaluation of Bids
31. Qualification of Bidder
32. Rejection of Bids
33. Re-Bidding
34. Announcement of Evaluation Report
35. Contacting the Procuring Agency
36. Grievances Redressal Award of Contract
37. Acceptance of Bid and Award Criteria
38. Procuring Agency's Right to vary quantities at the time of Award
39. Notification of Award.
40. Limitation on Negotiations

41. Signing of Contract
42. Performance Guarantee
43. Price Reasonability Certificate
44. Drug Act/DRAP Act Compliance

**SECTION III**

SCHEDULE OF REQUIREMENTS & TECHNICAL SPECIFICATIONS

**SECTION IV**

EVALUATION CRITERIA

**SECTION V**

BID FORM

BID COVER SHEET

BID FORM 1 BIDFORM2 BIDFORM3 BIDFORM4 BIDFORM5 BIDFORM6

**SECTION VI**

DRAFT STANDARD CONTRACT

Special Conditions of the Contract General Conditions of the Contract

# BID DATA SHEET

| ITB Reference | Description  | Detail  |
|---------------|--|---|
|               | <b>Pre-bid Date &amp; Time</b>   | <b><u>12-03-2026</u> at <u>11:00 A.M</u></b><br><b><u>VENUE:</u> Committee Room of DGHS</b>   |
| ITB Clause 24 | Last date and time for the receipt of bids on EPADS  | <b><u>LAST DATE FOR BID SUBMISSION</u> <u>31-03-2026 TILL</u> <u>11:00 A.M</u></b>  |
| ITB Clause 27 | Date, time and venue of opening of technical bids on EPADS   | <b>DATE: <u>31-03-2026</u> <u>AT 11:30 A.M</u></b><br><b>VENUE: Committee Room of DGHS</b>  |
| N/A           | Tender/Bid Reference No. (For Drugs / Medicines)   | <b>PC-01/Drugs/Medicines/26-27</b>  |
| ITB Clause 16 | Bid currency   | PKR on free delivery to Consignee's end basis including all Ex-work, Transportation, Storage charges till the destination (DDP Basis inclusive of all applicable taxes) |
| ITB Clause 13 | Language of bid  | English   |
| ITB Clause 20 | Amount of bid security   | <b>0.5%</b> of Estimated Cost as given in bidding document against each Item. Bid security shall have validity of at least 180 days                                     |
| ITB Clause 42 | Amount of performance security   | <b>04 %</b> of the total contract / award value   |
| ITB Clause 21 | Bid validity period  | 180 days from the date of the submission of bids  |
| ITB Clause 09 | Bidding procedure  | Single Stage – Two Envelope bidding procedure through EPADS   |
| ITB Clause 27 | <b>Directorate General Health Services, Punjab</b><br><b>24-Cooper Road, Lahore</b><br><b>Tel: +924299201145</b> |   |



## PURCHASE CELL

DIRECTORATE GENERAL HEALTH  
SERVICES PUNJAB  
24-COOPER ROAD, LAHORE



Health & Population Department

Phone No. +924299201145 Purchase Cell E-mail: pccdghs@gmail.com

## INVITATION FOR E-BIDS

Directorate General Health Services Punjab, 24-Cooper Road, Lahore invites E-bids from the eligible bidders for the Procurement of Goods through open competitive bidding for the financial year 2026-27.

| Name of Procurement   | Date and Time                                 |                      |
|---|---|----------------------|
| 1. Framework Contract for the Procurement of Medical Devices & Surgical Dressings etc. for DGHS, DHA's & All Vertical Programs under H&PD for the FY 2026-27.   | Pre-Bid Meeting<br>Date & Time                | 12/03/2026 11:00 AM. |
|   | Last date and time of<br>submission of tender | 31/03/2026 11:00 AM. |
| 2. Framework Contract for the Procurement of Drugs / Medicines for DGHS, DHA's & All Vertical Programs under H&PD for the FY 2026-27.   | Date and time of<br>opening of tender         | 31/03/2026 11:30 AM. |
|   |   |                      |
| 3. Framework Contract for the Procurement of Insulin, ASV, ARV, Erythropoietin, SK & other Biological / Bio Technical Items etc. for DGHS, DHA's & All Vertical Programs under H&PD for the FY 2026-27. |   |                      |
|   |   |                      |

The prospective bidders are required to quote competitive prices on delivered duty paid basis at the consignee's end. Interested eligible bidders may get the Bidding Documents and detailed specifications available on the websites of Punjab Procurement Regulatory Authority ([www.ppra.punjab.gov.pk](http://www.ppra.punjab.gov.pk)) & Directorate General Health Services, Punjab ([www.dghs.punjab.gov.pk](http://www.dghs.punjab.gov.pk)) and may be downloaded free of cost.

Bidding will be conducted through Single Stage - Two Envelopes bidding procedure as per Rule 38 (2) (a) of Punjab Procurement Rules 2014. (Amended)

Bid duly completed and conformity with bidding documents must be submitted online on E-Pak Acquisition and Disposal System (EPADS) website (i.e. <http://punjab.eprocure.gov.pk>). Original Bid security in favor of Directorate General Health Services Punjab in the shape of Bank Guarantee /CDR/Pay Order / Bank Draft / Call Deposit must be submitted physically at Purchase Cell, Directorate General Health Services Punjab, 24-Cooper Road Lahore. Bids submitted through EPADS shall only be entertained / accepted.

Note:

- All assessments and procuring procedure i.e. receiving, opening and awarding etc. shall be governed by the Punjab Procurement Rules 2014 (Amended).
- Bidders are advised to ensure uploading the bid on E-PADS Portal, well before the submission deadline, and not wait for the last date and time to upload the bid. Bid submission on E-PADS Portal shall entirely be the responsibility of the bidders. This office shall not be responsible for any issues.
- This Directorate may reject all bids or proposals at any time prior to the acceptance of a bid or proposal, as provided under Rule -35 of Punjab Procurement Rules, 2014.
- The URL of the website of the PPRA is (<http://eproc.punjab.gov.pk/ViewTender.aspx>) and response time shall be calculated exclusively from the date of publication of the advertisement on the website of the PPRA.

IPL- 2429

**DIRECTOR GENERAL HEALTH SERVICES PUNJAB**

**Section I**  
**Invitation to Bid**



**LETTER OF INVITATION**

**SUBJECT: INVITATION FOR BIDS OF DRUGS /MEDICINES THROUGH OPEN COMPETITIVE BIDDING FOR THE FINANCIAL YEAR 2026-27.**

Dear Sir/ Madam

Directorate General Health Services, Punjab (DGHS) has received authorization/ indents from the different procuring agencies of Health & Population department under 64-A of Punjab procurement rules for concluding the framework contract for the procurement of Drugs/ Medicines for FY 2026-27. DGHS is being concluding the framework contract at central level to ensure availability of medicines and attain uniformity, standardization, economy of scale and value of money for procurement of goods. DGHS and procuring agencies (who authorized / indented the DGHS for finalization framework contract) shall issue purchase orders to successful bidder against the requisitioned quantities.

2. DGHS invites e-Bids (Technical & Financial) from local pharmaceutical manufacturers/sole Agents of foreign manufacturers for the supply of Drugs /Medicines through open competitive bidding for the FY 2026-27 on free delivery to Consignee's end basis (DDP basis). Detailed technical specifications along with quantities of Drugs /Medicines are given in the bidding documents.

3. The bidder must bid for entire/total quantity. Bid for partial quantity will straightway be rejected.

4. Interested eligible bidders may also get the bidding documents including detailed specifications from the websites of Punjab Procurement Regulatory Authority ([www.ppra.punjab.gov.pk](http://www.ppra.punjab.gov.pk)) & Directorate General Health Services, Punjab ([www.dghs.punjab.gov.pk](http://www.dghs.punjab.gov.pk)) free of cost.

5. Bidding shall be conducted through Single Stage – Two Envelopes bidding procedure of Punjab Procurement Rules, 2014. Bid duly completed and conformity with bidding documents must be submitted online on E-Pak Acquisition and Disposal System (EPADS) website (i.e., <http://punjab.eprocure.gov.pk> ). **Original 0.5 % Bid security of estimated cost of each item in favor of Directorate General Health Services Punjab in the shape of Bank Guarantee /CDR/Pay Order / Bank Draft/ Banker's cheque must be submitted physically at Purchase Cell, Directorate General Health Services Punjab, 24-Cooper Road Lahore on or before 31-03- 2026 till 11:00 A.M. Bids submitted through EPADS shall only be entertained / accepted.** The rate offered must be inclusive of all taxes levied by the Government. Bids will be opened publicly in the presence of the bidders/their representatives who may choose to be present at **11:30A.M** at Conference Room, Directorate General Health Services Punjab.

6. The bids shall be marked as "FINANCIAL PROPOSAL" and TECHNICAL PROPOSAL" in bold and legible letters. The bids shall clearly be **marked with Tender Enquiry No.** for which the proposal is submitted. Financial Proposal of bids found technically non-responsive shall not be opened on EPADS. Item(s) shall be quoted in

Technical & Financial Proposal with both Brand Name(s) and generic name. **It is advised that E-financial proposals should be submitted separately for each quoted item through online.**

**7. Pre-bid meeting** to held on **12-03-2026 at 11:00 A.M** in the committee room of Directorate General Health Services Punjab, 24-Cooper Road Lahore. Minutes of meeting of pre-bid meeting shall be part of bidding document.

**8.** The last date and time for online bid submission on E-Pak Acquisition and Disposal System (EPADS) is **31-03-2026 up till 11:00 A.M.** which shall be opened on the same date at **11:30 A.M.**

**9.** All documents submitted on EPADS should contain proper page marking, attached in sequence as indicated for evaluation in the bidding Documents and signatures of authorized person. Moreover, signing and stamping of each page of bidding documents/form is mandatory.

**10.** In case the date of opening is declared as a public holiday by the government or non-working day due to any reason, the next official working day shall be deemed to be date of submission of original bid security & opening of the bid. However, interested bidder must submit its bid (Technical & Financial proposal) on EPADS on or before closing date i.e., 31-03-2026 up till 11:00A.M. In case of non- submission of the bids on EPADS procuring agency shall not be responsible. No such claims shall be entertained in this regard.

**Note:**

- 1) The Procurement/Bidding Process shall be governed by the Punjab Procurement Rules, 2014 (Amended).**
- 2) Purchase orders shall be issued by procuring agency as specified against the demand of each item. However, DGHS may issue purchase order on behalf of any other procuring agency or against the reserved / un-utilized quantities. DGHS may also authorize any procuring agency to issue purchase order against un-utilized quantities. Low quantity items (case to case basis) may be received at DGHS Punjab against the purchase order issued by procuring agency for test / analysis and subsequent distribution.**
- 3) This tender uploaded on EPADS as Part A (Sr. 01-90) and as Part B (Sr. 91-178)**

**Director General Health Services,  
Punjab**

*Bidders are advised to read the contents of the Instruction to Bidders (ITB) carefully*

**Section II**  
**Instructions to Bidder**

## **1. Scope of Bid**

- 1.1.** DGHS, Government of the Punjab, invites e-bids from local Pharmaceutical Manufacturers/Sole Agents of Foreign Manufacturers for supply of Drugs /Medicines through open competitive bidding for Health Facilities in Punjab working under the administrative control of Health & Population Department, as per quantities and specifications more specifically described in **Section III of the Tender Documents** Schedule of Requirements & Technical Specifications.

## **2. Source of Funds**

- 2.1.** Government of the Punjab

## **3. Eligible Bidders**

- 3.1.** This Invitation to Bid is open to all local pharmaceutical manufacturers/ sole agents of foreign manufacturers/Principals in Pakistan by DGHS for the year 2026-27 for supply of Drugs/Medicines through open competitive bidding more specifically described in the Section III, Schedule of Requirements & Technical Specifications.
- 3.2.** The Sole Agent/Importer must possess valid authorization from the Manufacturer and shall have to submit a copy of Memorandum of Association/Partnership deed registered with the Registrar of Companies. However, in case of Manufacturer, they should have a documentary proof as prescribed in the Section V, Bid Form, to the effect that they are the original Manufacturer of the required specifications of Goods.

## **4. Corrupt or Fraudulent Practices and Mechanism to Debar/Blacklist the Defaulted Bidder**

- 4.1.** The Government of Punjab defines Corrupt and Fraudulent Practices as “the offering, giving, receiving, or soliciting of anything of value to influence the action of a public official or the contractor in the procurement process or in contract execution to the detriment of the procuring agency; or misrepresentation of facts in order to influence a procurement process or the execution of a contract, collusive practices among bidders (prior to or after bid submission) designed to establish bid prices at artificial, non-competitive levels and to deprive the procuring Agency of the benefits of free and open competition and any request for, or solicitation of anything of value by any public official during the exercise of his duty; it may include any of the following practices:
- (i) *coercive practice by impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence the actions of a party to achieve a wrongful gain or to cause a wrongful loss to another party.*
  - (ii) *Collusive practice by arrangement between two or more parties to the procurement process or contract execution, designed to achieve with or without the knowledge of the procuring agency to establish prices at artificial, noncompetitive levels for any wrongful gain.*
  - (iii) *Corrupt practice by offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence the acts of another party for wrongful gain.*
  - (iv) *fraudulent practice by any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation.*
  - (v) *obstructive practice by harming or threatening to harm, directly or*

*indirectly, persons or their property to influence their participation in a procurement process, or affect the execution of a contract or deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements before investigators in order to materially impede an investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation, or acts intended to materially impede the exercise of inspection and audit rights;*

- 4.2.** Indulgence in corruption and fraudulent practices is liable to result in rejection of Bids, cancellation of contracts, debarment and blacklisting of the Bidder, for a stated or indefinite period.
- 4.3.** The following are the events which would lead to initiate under the PPRA Rules 2014 Blacklisting / Debarment process.
- i. Submission of false fabricated / forged documents for procurement in tender.
  - ii. Not attaining required quality of work.
  - iii. Inordinate tardiness in accomplishment of assigned/agreed responsibilities / contractual obligations resulting loss to procuring agency / Government
  - iv. Non-execution of work as per terms & condition of contract.
  - v. Any unethical or unlawful professional or business behavior detrimental to good conduct and integrity of the public procurement process.
  - vi. Involvement in any sort of tender fixing.
  - vii. Persistent and intentional violation of important conditions of contract
  - viii. Non-adherence to quality specification despite being importunately pointed out.
  - ix. Security consideration of the State i.e., any action that jeopardizes the security of the State or good repute of the procuring agency.

**PROCEDURE:** The procedure mentioned in Punjab Procurement Rules 2014 will be followed

## **5. Eligible Goods and Services**

- 5.1.** All goods and related services to be supplied under the contract shall conform to the policies of the Government of Punjab in vogue. All expenditures made under the contract shall be limited to such goods and services. For purposes of this clause, (a) the term "Goods" includes any goods that are the subject of this Invitation for Bids and (b) the term "Services" includes related ancillary services such as transportation, insurance, after sale service etc.

## **6. Cost of Bidding**

- 6.1.** The Bidder shall bear all costs associated with the preparation and submission of its bid, and the Procuring Agency shall in no case be responsible or liable for those costs, regardless of the conduct or outcome of the bidding process.

## **7. Bidding for Selective Items**

- 7.1.** A Bidder, if he so chooses, can bid for selective items from the list of goods provided in the Section III i.e., Schedule of Requirements & Technical Specifications. A Bidder is also at a liberty to bid for all the items mentioned in the Section III i.e., Schedule of Requirements & Technical Specifications. However, Bidders cannot bid for partial quantities of an item mentioned in

Section III i.e., Schedule of Requirements & Technical Specifications. **THE BID MUST BE FOR THE TOTAL QUANTITY OF AN ITEM REQUIRED IN THE SECTION III i.e., SCHEDULE OF REQUIREMENTS & TECHNICAL SPECIFICATIONS.**

## **THE BIDDING PROCEDURE**

### **8. The Governing Rules**

**8.1. The Bidding procedure shall be governed by the Punjab Procurement Rules, 2014 (Amended), of the Government of Punjab.**

### **9. Applicable Bidding Procedure**

9.1. "Single stage – Two Envelops bidding procedure" shall be employed.

#### ***Single Stage: Two Envelope Bidding Procedure through EPADS***

*Single stage two envelopes bidding procedure shall be used for procurement of such goods where the bids are to be evaluated on technical and financial grounds and the procedure for single stage two envelopes shall be:*

- (i) The bid shall be a single package consisting of two separate envelopes, containing separately the financial and the technical proposals.*
- (ii) the envelopes shall be marked as "Financial Proposal" and "Technical Proposal";*
- (iii) in the first instance, the "Technical Proposal" shall be opened, and the envelope marked as "Financial Proposal" shall be retained unopened in the custody of the procuring agency.*
- (iv) the procuring agency shall evaluate the technical proposal in the manner prescribed in advance, without reference to the price and shall reject any proposal which does not conform to the specified requirements.*
- (v) during the technical evaluation no amendments in the technical proposal shall be permitted.*
- (vi) after the evaluation and approval of the technical proposals, the procuring agency shall open the financial proposals of the technically accepted bids, publicly at a time, date and venue announced and communicated to the bidders in advance, within the bid validity period.*
- (vii) The financial bids found technically nonresponsive shall be returned unopened to the respective bidders; and*
- (viii) the lowest evaluated bidder shall be awarded the contract;*

## **THE BIDDING DOCUMENTS**

### **10. Contents of the Bidding Documents**

10.1. The goods required, applicable bidding procedures, and Contract terms are prescribed in the Bidding Documents. In addition to the Invitation for Bids, the Bidding Documents include:

- (a) Instructions to Bidders (ITB)(Section-II)
- (b) Schedule of Requirements & Technical Specifications (Section-III)
- (c) Evaluation Criteria (Section-IV)
- (d) Bid Forms (Section-V)
  - i) Letter of Intention
  - ii) Affidavit
  - iii) Technical Forms
  - iv) Financial Forms
- (f) Draft Standard Contract (Section-VI)
  - i. Contract Form
  - ii. General Conditions of the Contract
  - iii. Special Conditions of Contract,

- 10.2. The "Invitation for Bids" is not a formal part of the Bidding Documents and is included as a reference only. In case of discrepancies between the Invitation for Bid and the Bidding Documents listed in 10.1 above, the Bidding Documents shall take precedence.
- 10.3. The Bidder is expected to examine all instructions, forms, terms and specifications in the Bidding Documents. Failure to furnish all information required by the Bidding Documents or to submit a bid not substantially responsive to the Bidding Documents in every respect shall be at the Bidder's risk and may result in the rejection of its bid.

#### **11. Clarification(s) on Bidding Documents**

- 11.1. A prospective Bidder requiring any clarification(s) on the Bidding Documents may notify the Procuring Agency in writing at the Procuring Agency's address indicated in the Bid Data Sheet. The Procuring Agency shall respond in writing to any request for clarification(s) of the bidding documents, which it receives no later than **Seven (07) days** prior to the deadline for the submission of bids prescribed in the Invitation for Bids. Written copies of the Procuring Agency's response (including an explanation of the query but without identifying the source of inquiry) shall be sent to all prospective Bidders that have received the Bidding Documents.

#### **12. Amendment(s) to the Bidding Documents**

- 12.1. At any time prior to the deadline for submission of bids, the Procuring Agency, for any reason, whether at its own initiative or in response to a clarification(s) requested by a prospective Bidder, may modify the Bidding Documents by amendment(s).
- 12.2. All prospective Bidders that have received the Bidding Documents shall be notified of the amendment (s) in writing through EPADS, and shall be binding on them.
- 12.3. To allow prospective Bidders reasonable time for taking the amendment(s) into account in preparing their bids, the Procuring Agency, at its discretion, may extend the deadline for the submission of bids through corrigendum.

### **PREPARATION OF BIDS**

#### **13. Language of Bids.**

- 13.1. All correspondence, communications, associated with preparation of Bids, clarifications, amendments, submissions shall be written either in English or Urdu or both languages. Supporting documents and printed literature furnished by the Bidder may be in another language provided they are accompanied by an accurate translation of the relevant passages in English or Urdu, in which case, for purposes of interpretation of the Bid, the said translation shall take precedence.

#### **14. Documents Comprising the Bids.**

- 14.1. The Bid shall comprise of the BID FORMs, UNDERTAKING, TECHNICAL DETAIL OF THE PRODUCT, of this Bidding Document and all those ancillary documentations that are prescribed for the eligibility of the goods and ancillary services that are found necessary and highlighted in the Bid Forms in Section V.
- 14.2. The Bidder shall complete the BID FORM and an appropriate PRICE SCHEDULE furnished in the bidding documents, indicating the goods to be supplied, a brief description of the goods, their general and specific characteristics, ancillary services that the bidder is willing or required to provide

along with the proposed price.

**15. Bid Price.**

- 15.1. The Bidder shall indicate on the appropriate form, prescribed in this Bidding Documents, the unit prices and total bid price of the goods, it proposes to supply on free delivery to the consignee end under the Contract.
- 15.2. Form prescribed for quoting of prices is to be filled in very carefully, preferably typed. Any alteration/correction must be initialed. Every page is to be signed and stamped at the bottom.
- 15.3. The Bidder should quote the prices of goods according to the technical specifications as provided in Section III of this document. The technical specifications of goods, different from the required specifications, shall straightway be rejected.
- 15.4. The Bidder is required to offer a competitive price. All prices must include the taxes and duties, where applicable and all Ex- work & inland transportation & storage charges till the destination (on free delivery to Consignee's end basis). If there is no mention of taxes, the offered/quoted price shall be considered as inclusive of all prevailing taxes/duties. –
- 15.5. The benefit of exemption from or reduction in the taxes and duties shall be passed on to the Procuring Agency.
- 15.6. Prices offered should be for the entire quantity of an item demanded in the Section III i.e., Schedule of Requirement & Technical Specifications; partial quantity offers shall straightway be rejected. Conditional offer shall also be considered as non-responsive bid.
- 15.7. While making a price quote, trend/inflation in the rate of goods and services in the market should be kept in mind. No request for increase in price due to market fluctuation in the cost of goods and services shall be entertained.

**16. Bid Currencies.**

- 16.1. Prices shall be quoted in Pak Rupees (PKR) on free delivery to Consignee's end basis including all Ex-work, Transportation, Storage charges till the destination (DDP Basis).

**17. Samples**

- 17.1. The Bidder shall provide samples of quoted goods along with the bid at his own cost and in a quantity prescribed by the Procuring Agency in Section III

**18. Documentation on Eligibility of Bidders.**

- 18.1. Bidder shall furnish, as part of its bid (Bid Form) as specified in Section V, documents establishing the Bidder's eligibility to bid and its qualifications to perform the Contract if its bid is accepted.
- 18.2. The documentary evidence of the Bidder's eligibility to bid shall establish to the Procuring Agency's satisfaction that the Bidder, at the time of submission of its bid, is an eligible as defined under ITB Clause 3 above.

**19. Documentation on Eligibility of Goods.**

- 19.1. The Bidder shall furnish, as part of its bid (Bid Form) as specified in Section V, documents establishing the eligibility and conformity to the bidding documents of all goods, which the Bidder proposes to supply under the Contract.

**20. Bid Security**

20.1. The bidder shall submit as specified in invitation of bids and upload copy of bid security with Technical bid & Financial Proposal

**21. Bid Security**

21.1. Bids shall remain valid for the period identified in the Bid Data Sheet after the date of opening of technical bid prescribed by the Procuring Agency. A bid valid for a shorter period shall be rejected by the Procuring Agency as non-responsive.

21.2. The Procuring Agency shall ordinarily be under an obligation to process and evaluate the bid within the stipulated bid validity period. However, under exceptional circumstances and for reason to be recorded in writing, if an extension is considered necessary, all those who have submitted their bids shall be asked to extend their respective bid validity period. Such extension shall be for not more than the period equal to the period of the original bid validity.

21.3. Bidders who:-

- (a) agree to the Procuring Agency's request for extension of bid validity period shall not be permitted to change the substance of their bids; and
- (b) Do not agree to an extension of the bid validity period shall be allowed to withdraw their bids without forfeiture of their bid securities.

**22. Format and Signing of Bids.**

22.1. The Bidder shall prepare and submit its bid on EPADS and provide original documents, as appropriate. Copies of any documents must be signed and stamped by the bidder.

22.2. The original bid shall be typed or written in indelible ink. All documents should contain proper page marking, attached in sequence as indicated for evaluation in the bidding document and signatures of authorized person. Moreover, signing and stamping of each page of bidding document/form is mandatory.

22.3. Any interlineations, erasures, or overwriting shall be valid only if they are initialed by the person or persons signing the bid.

**22(a). Submission of Bids/Proposals.**

The bidder must submit Bid/Proposal on EPADS before date and time mentioned in letter of invitation.

All blank fields are mandatory to fill/complete and submit copy of bidding document (on EPADS) and relevant required documents with page number mentioned on each page with sign and stamp. The bid shall be a single package consisting of two separate envelopes, containing separately the financial and the technical proposals (on EPADS).

**23. Sealing and Marking of Bids.**

23.1. The envelopes shall be marked as "FINANCIAL PROPOSAL" and "TECHNICAL PROPOSAL" in bold and legible letters to avoid confusion. Similarly, the Bidder shall seal the proposals/bids. The envelopes shall then be sealed in an outer envelope marked with **Bid Reference Number & Tender No.**

23.2. The inner and outer envelopes shall:

- (a) be addressed to the Procuring Agency at the address given in the Invitation for Bids; and
- (b) Bid Reference, Tender No./ Items No. indicated in **Section III, Schedule of Requirements & Technical Specifications** and a statement: "DO NOT OPEN BEFORE," the time and the date specified for

opening of Bids.

- 23.3. The inner envelopes shall also indicate the name and address of the Bidder to enable the bid to be returned unopened in case it is declared as “non-responsive” or “late”.
- 23.4. If the outer as well as inner envelope is not sealed and marked as required by 23.1 to 23.4 above the Procuring Agency shall assume no responsibility for the bid’s misplacement or premature opening.

**24. Deadline for Submission of Bids**

- 24.1. All bids should be submitted on EPADS. Bids must be submitted by the Bidder on EPADS on the time and date specified in the Bid Data Sheet. **Bids submitted on EPADS later than the time and date specified in the Advertisement/Bid Data Sheet will stand summarily rejected.**
- 24.2. The Procuring Agency may, in its discretion, extend the prescribed deadline for the submission of bids by amending the bidding documents in accordance with ITB Clause 12 above, in which case all rights and obligations of the Procuring Agency and Bidders previously subject to the deadline shall thereafter be subject to the deadline as extended.

**25. Late Bids**

- 25.1. Any bid received on EPADS after the deadline for submission of bids prescribed by the Procuring Agency pursuant to ITB Clause 24 shall be rejected and returned unopened to the Bidder.

**26. Withdrawal of Bids**

- 26.1. The Bidder may withdraw its bid after the bid’s submission and prior to the deadline prescribed for submission of bids.
- 26.2. No bid may be withdrawn in the period between deadline for submission of bids and the expiration of the period of bid validity specified in Bid Data Sheet. Withdrawal of a bid during this period may result in initiation of legal action against the firm.

**OPENING AND EVALUATION OF BIDS**

**27. Opening of Bids by the Procuring Agency.**

- 27.1. All bids received on EPADS, shall be opened by the Procuring Agency publicly in the presence of the Bidders or their authorized representatives, who chose to attend the bid opening, on the date, time and venue prescribed in the Bid Data Sheet.
- 27.2. The opening of Bids shall be subject to the Bidding Procedure prescribed in the Bid Data Sheet and elaborated in ITB Clause 9 above.
- 27.3. All Bidders in attendance shall sign an attendance sheet.
- 27.4. The Procuring Agency shall open one Bid at a time and read out aloud its contents which may include name of the Bidder, items quoted for and unit prices and total amount of the Bid (if applicable). The Procuring Agency may choose to announce any other details which it deems appropriate if not in conflict with the Punjab Procurement Rules-2014.
- 27.5. The Procuring Agency shall have the minutes of the Bid opening (Technical and when applicable Financial) recorded.
- 27.6. No bid shall be rejected at Technical Proposal/Bid opening, except for late bids, which shall be returned unopened to the Bidder, the Chairman of the Purchase/Procurement Committee shall record a statement giving reasons for return of such bid(s).

**28. Clarification of Bids.**

28.1. During evaluation of the bids, the Procuring Agency may, at its discretion, ask the Bidder for a clarification of its bid. The request for clarification and the response shall be in writing, and no change in the prices or substance of the bid shall be sought, offered, or permitted.

**29. Preliminary Examination.**

29.1. The Procuring Agency shall examine the bids to determine whether they are complete, whether any computational errors have been made, whether required sureties have been furnished, whether the documents have been properly signed, and whether the bids are generally in order.

29.2. In the Financial Bids, the arithmetical errors shall be rectified on the following basis.

- a) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail, and the total price shall be corrected.
- b) If the Bidder does not accept the correction of the errors, its bid shall be rejected, and its Bid Security may be forfeited.
- c) If there is a discrepancy between words and figures, the amount in words shall prevail.

29.3. The Procuring Agency may waive any minor informality, nonconformity, or irregularity in a bid which does not constitute a material deviation, provided such waiver does not prejudice or affect the relative ranking of any Bidder.

29.4. Prior to the detailed evaluation, the Procuring Agency shall determine the substantial responsiveness of each bid to the bidding documents. For purposes of this clause, a substantially responsive bid is one, which conforms to all the terms and conditions of the bidding documents without material deviations. Deviations from, or objections or reservations to critical provisions, such as those concerning Applicable Laws, Taxes & Duties and internationally recognized best practices shall be deemed to be a material deviation for Technical Proposals. The Procuring Agency's determination of a bid's responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence.

29.5. If a bid is not substantially responsive, it shall be rejected by the Procuring Agency and may not subsequently be made responsive by the Bidder by correction of the nonconformity.

**30. Evaluation of Bids.**

30.1. The Procuring Agency shall evaluate and compare the bids, which have been determined to be substantially responsive in accordance with ITB Clause 29 above.

30.2. All bids shall be evaluated in accordance with the Evaluation Criteria Least Cost Method and other terms and conditions set forth in these bidding documents.

30.3. For the purposes of comparison of bids quoted in different currencies, the price shall be converted into Pak Rupees. The rate of exchange shall be the selling rate, prevailing on the date of opening of Financial Bids specified in the bidding documents, as notified by the State Bank of Pakistan/National Bank of Pakistan on that day, if required on C&F basis.

30.4. A bid once opened in accordance with the prescribed procedure shall be subject to only those rules, regulations and policies that are in force at the time of issue of notice for invitation of bids.

### **31. Qualification of Bidder**

- 31.1. The Procuring Agency, at any stage of the procurement proceedings, having credible reasons for or prima facie evidence of any defect in Bidder's capacity may require the Bidder to provide information concerning their professional, technical, financial, legal or managerial competence whether already pre-qualified.
- 31.2. The procuring Agency may conduct surprise inspection either itself or through third party of firms during validity of bid period, however in case of unsatisfactory compliance condition to the standards; the procuring agency reserves the right to initiate legal proceedings besides disqualification.
- 31.3. Such qualification shall only be laid down after recording reasons thereof in writing. They shall form part of the records of that procurement proceeding.
- 31.4. The Procuring Agency shall determine to its satisfaction whether a Bidder, technically and financially qualified and even having the lowest evaluated responsive bid is qualified to perform the Contract satisfactorily.
- 31.5. The determination can consider the Bidder's financial, technical, and production capabilities. It shall be based upon an examination of the documentary evidence of the Bidder's qualifications submitted by the Bidder, as well as such other information as the Procuring Agency deems necessary and appropriate. Further, during the process of technical evaluation of Bidder, the Procuring Agency may inspect the manufacturing plant/production capacity/warehousing system/practices by a team of experts for assessment, if it deems necessary.
- 31.6. An affirmative determination shall be a prerequisite for award of the Contract to the Bidder. A negative determination shall result in rejection of the Bidder's bid, in which event the Procuring Agency shall proceed to the next lowest evaluated bid to make a similar determination of that Bidder's capabilities to perform satisfactorily.
- 31.7. The Procuring Agency shall disqualify a Bidder if it finds, at any time, that the information submitted by him concerning his qualification as Bidder was false and materially inaccurate or incomplete.

### **32. Rejection of Bids**

- 32.1. The Procuring Agency may reject any or all bids at any time prior to the acceptance of a bid in accordance with Punjab Procurement Rules-2014 (PPR-2014 amended to date). The Procuring Agency shall upon request communicate to any Bidder who submitted a bid, the grounds for its rejection of any or all bids but is not required to justify those grounds.
- 32.2. The Procuring Agency incurs no liability, solely by virtue of its invoking Clause 32.1 towards Bidders who have submitted bids.
- 32.3. Notice of the rejection of any or all bids shall be given promptly to the concerned Bidders that submitted bids.

### **33. Re-Bidding**

- 33.1. If the Procuring Agency rejects all bids in pursuant to ITB Clause 32, it may call for a re-bidding. The Procuring Agency, if it deems necessary may prescribe another method of procurement not inconsistent with the Punjab Procurement Rules-2014.
- 33.2. The Procuring Agency before invitation for re-bidding shall assess the reasons for rejection and may revise specifications, evaluation criteria or any other condition for Bidders, as it may deem necessary.

**34. Announcement of Evaluation Report**

34.1. The Procuring Agency shall announce the results of the bid evaluation in form of a report, not inconsistent with the Punjab Procurement Rules, 2014, giving justification for acceptance or rejection of bids at least ten days prior to the award of procurement Contract.

**35. Contacting the Procuring Agency**

35.1. Subject to ITB Clause 28 above, no Bidder shall contact the Procuring Agency on any matter relating to its bid, from the time of the bid opening to the time of announcement of Evaluation Report. If a Bidder wishes to bring additional information to the notice of the Procuring Agency, it should do so in writing.

35.2. Any effort by a Bidder to influence the Procuring Agency in its decisions on bid evaluation, bid comparison, or Contract award may result in the rejection of the Bidder's bid. Canvassing by any Bidder at any stage of the bid evaluation is strictly prohibited. Any infringement shall lead to disqualification.

**36. Grievance Redressal**

36.1. As per Rule-67 of PPR-14, Procuring Agency shall constitute a Grievance Redressed Committee (GRC) comprising of odd number of persons with proper powers and authorization to address the complaints. The GRC shall not have any of the members of the Procurement Evaluation Committee. The Committee may preferably have one subject specialist depending upon the nature of the procurement in addition to one person with legal background as per their availability to the Procuring Agency.

36.2. Any Bidder feeling aggrieved can file its written complaint against the eligibility parameters or any other terms and conditions prescribed in the Bidding documents found contrary to provision of Rule 33, and the same shall be addressed by the Procuring Agency well before the proposal submission deadline.

36.3. Any party can file its written complaint against the eligibility parameters or any other terms and conditions prescribed in the bidding documents found contrary to provision of Rule 34 and the same shall be addressed by the Procuring Agency well before the proposal submission deadline.

36.4. Any Bidder feeling aggrieved by any act of the Procuring Agency after the submission of his Bid may lodge a written complaint concerning his grievances not later than ten days after the announcement of the Final evaluation reports. In case of single stage - two envelope bidding procedure, any bidder feeling aggrieved from technical evaluation may file a grievance within 5 days of announcement of the technical evaluation report. After completion of the technical evaluation process, the procuring agency shall immediately upload the technical evaluation report on the website of PPRA and Procuring Agency for obtaining/ receiving grievance petitions from the prospective bidders (if any).

36.5. In case, the complaint/grievance is filed after the issuance of the final evaluation report, the complainant cannot raise any objection on technical evaluation of the report. Provided that the complainant may raise the objection on any part of the final evaluation report in case where single stage one envelop bidding procedure is adopted.

36.6. The GRC shall investigate and decide upon the complaint within fifteen days of the receipt of the complaint. Mere fact of lodging of a complaint shall not warrant suspension of the procurement process.

## **AWARD OF CONTRACT**

### **37. Acceptance of Bid and Award Criteria**

37.1. The Bidder whose bid is found to be most closely conforming to the Evaluation Criteria prescribed in Section IV and having the lowest evaluated bid, if not in conflict with any other law, rules, regulations, or policy of the Punjab Government, shall be awarded the Contract, within the original or extended period of bid validity.

### **38. Procuring Agency's Right to vary quantities at the time of Award as per PP Rule 59 (c)-iv**

38.1. The Procuring Agency may vary in quantities as per Punjab procurement rule 59 (c)-iv against the quantity of goods originally specified in Section III i.e., Schedule of Requirements & Technical Specifications without any change in unit price and other terms & conditions as per PPRA 2014.

### **39. Notification of Award**

39.1. Prior to the expiration of the period of bid validity, the Procuring Agency shall notify the successful Bidder in writing that its bid has been accepted.

39.2. DGHS under the administrative control of Health & Population Department will issue the Notification of Award. DGHS is being concluding the framework contract at central level to ensure availability of medicines and attain uniformity, standardization, economy of scale and value of money for procurement of goods. DGHS and procuring agencies (who authorized / indented the DGHS for finalization framework contract) shall issue purchase orders to successful bidder against the requisitioned quantities. The successful bidder shall submit the required Performance guarantee to DGHS, Punjab against the total approved quantity within 10 (TEN) days after issuance of AAT. After receipt of Performance Guarantee, the DGHS will sign the Contract and subsequently Purchase Orders will be issued by the DGHS & procuring agencies accordingly.

39.3. The enforcement of the Contract shall be governed by Rule 63 of Punjab Procurement Rules-2014.

### **40. Limitation on Negotiations.**

40.1. Save and otherwise provided in PPR-2014, Procuring Agency shall not negotiate with any bidder.

### **41. Signing of Contract.**

41.1. The Framework Contract is to be made on stamp Paper worth of Rs. 1200 and procuring agencies shall receive stamp duties @ 25 paise per every one hundred rupees of the total value of the purchase order, under section 22(A)(B) of schedule 1 of Stamp Duty Act 1899 read with Finance Act 1995 (Act-VI of 1995) Notification No. JAW/HD/8- 21/77 (PG) dated 1st January 2014.

### **42. Performance Guarantee.**

42.1. Before signing of Framework Contract, the successful Bidder shall furnish a Performance Guarantee of **04%** of awarded item(s), on the Form and in the mannered prescribed by the Procuring Agency.

42.2. The Bid Security submitted by the bidder at the time of submitting its bid shall be returned to the Bidder upon submission of Performance Guarantee.

42.3. Failure to provide a Performance Guarantee by the Bidder is a sufficient ground for annulment of the award and forfeiture of Bid Security. In such event the

Procuring Agency may award the Contract to the next lowest evaluated bidder or call for new bid.

**43. Price Reasonability.**

43.1. The prices quoted shall not be more than the Trade Prices as per MRP (Maximum Retail Price) fixed by the Federal Government under Drugs Act, 1976/DRAP Act, 2012.

**44. Drugs Act/ DRAP Act Compliance.**

All supplies will comply with the provision of Drugs Act 1976/DRAP Act 2012 and Punjab Drugs (Amendments) Act 2017 and rules framed there under.

**Section III**  
**SCHEDULE OF**  
**REQUIREMENTS &**  
**TECHNICAL**  
**SPECIFICATIONS**

**LIST, TECHNICAL SPECIFICATIONS & QUANTITIES FOR  
DRUGS/MEDICINES (FY 2026-27).**

**Drugs/Medicines**

**List of items along with technical specifications attached as Annexure**

**Note:**

1. The estimated cost is for calculation of bid security only. Moreover, in case of variation in pack size of dosage form (liquid) rates will be calculated on per ml basis (Where allowed in technical specifications).
2. The packaging of glass bottle (oral/injectable) and plastic bottle/HDPE/PVDC material shall be as per submitted commercial samples for the pharmaceutical finished product packaging.
3. Certificate regarding fulfillments of requirements under Bio Safety Act 2005 and the rules framed there under must be attached for Vaccines/Sera, Biotechnical products etc.
4. For experience of the quoted product, the experience of offered pack size/volume will be considered.
5. For thermo-labile drugs for which storage temperature is 2-8 degree centigrade. The firm shall be bound to produce batch wise cold chain data from the source of origin & thermo-log data from the factory to Consignee's end.
6. The quoted product must comply with conditions of Drug Registration Certificate (Specification, Labeling, Packaging, Manufacturing, Testing etc.)
7. **Any further information can be obtained from the office of Purchase cell DGHS Address 24-Cooper Road Lahore.**

**Section IV**  
**EVALUATION CRITERIA**

**CRITERIA (DRUG/MEDICINE ITEMS)**  
**A- FOR LOCAL MANUFACTURERS - (KNOCK DOWN CRITERIA FIRM WISE)**

| Sr | BIDDING DOCUMENTS PARAMETERS 2026-27   |
|----|--|
| 1. | Valid Drugs Manufacturing License issued by DRAP as per rules.   |
| 2. | Valid GMP Certificate OR Valid Satisfactory GMP Inspection Report issued by DRAP. (Only those Sections & Pharmaceutical Category will be considered for evaluation whose GMP Inspection Report declared satisfactory and/ or are mentioned in the GMP Certificate).<br>The bidders which have valid GMP till 30.09.2025 and they have applied for renewal of GMP certificate till 01.11.2025 but the inspection has not been conducted, will be considered eligible against this parameter. However, the bidder shall submit an acknowledgement receipt from DRAP & undertaking that inspection has not been conducted or there is no critical/major observation of the inspection by DRAP (in case inspection has been conducted).  |
| 3. | The bidder shall submit SOP`s regarding drug recall.   |
| 4. | Bidder should have a valid NTN, GST, and Active Taxpayer Status verifiable from FBR website.   |
| 5. | The bidder shall undertake applicable e-stamp paper of PKR 300 issued by the Government of Punjab regarding: <ul style="list-style-type: none"> <li>i. The bidder is not currently blacklisted/ debarred by Directorate General Health Services (DGHS) Punjab/ PPRA.</li> <li>ii. All relevant manufacturing equipment and processes must be calibrated and validated in accordance with the bidder's annual plan. Sections found to be non-compliant will not be eligible for consideration in the bidding process. The bidder will annex the list of all such equipment along with make, model, serial no., year of installation and current calibration dates on its letter head. All such data must be verifiable. The bidder shall undertake that the equipment calibration service provider has duly been passed through vendor qualification process.</li> <li>iii. That the bidder must have microbiology lab independent from other quality control laboratories.</li> <li>iv. That the bidder must have an independent quality assurance section.</li> <li>v. The quality control or microbiology lab is equipped with all necessary and functional instruments/ equipment required to perform official tests on the quoted items, ensuring none are missing or deficient. All such equipment must be calibrated. The bidder will annex the list of all such equipment along with make, model, serial no., year of installation and current calibration dates on its letter head. All such data must be verifiable.</li> <li>vi. Facility has functional and validated Heating, Ventilation &amp; Air Conditioning System (HVAC) as per the master validation plan.</li> <li>vii. R.O Water/ De-ionized water Plant is available and functional. The bidder is having the latest calibration certificate.</li> <li>viii. Bidder is having minimum two calibrated functional stability chambers along with calibration/ validation certificate/ record for the real time and accelerated stability studies.</li> <li>ix. None of its supplied samples of quoted section has been declared Spurious/ Adulterated from any DTL of Punjab since 01.01.2023 till the closing date of documents submission. The claim of the bidder shall be verified from PQCB, Punjab.</li> <li>x. The bidder shall be bound to supply the stock in compliance with SRO 470(I)/2017 subject to requirement of the department.</li> </ul> |

|   |  |
|---|--|
|   | <p>xi. That the Information provided is in accordance with the terms &amp; conditions of the documents and the bidder accepts all the terms and conditions of the documents.</p> <p>xii. The bidder shall be bound to supply packaging material of medicines and medical devices in accordance with the approved sample of commercial pack.</p>  |
| 6.  | Affidavit as per bid form 2  |
| 7.  | The bidder will submit Original 0.5 % Bid security of estimated cost of each item having validity of at least 180 days in favor of Directorate General Health Services Punjab in the shape of Bank Guarantee / CDR/ Pay Order / Banker's cheque must be submitted physically at Purchase Cell, Directorate General Health Services Punjab, 24-Cooper Road Lahore on or before <b>31-03-2026 till 11:00 A.M.</b>  |
| 8.  | The bidder must submit bio similarity studies data of quoted item (for biological and biotech products). The biosimilar products should submit biosimilar study from DRAP notified labs or WHO/ JPMHLW/ EMA/ US FDA approved/accredited labs only OR quoted product must have status of reference product for biosimilar studies on USA FDA/ registered at EMA official websites.  |
| 9.  | Two packs of samples (Samples must be commercial packs). Specifications quoted in the technical offer will be verified from samples provided versus product registration certificate. Products that comply 100% with the required specifications and fulfill the requirements as per labeling & packing rules shall be considered.   |
| <b>2-KNOCK DOWN CRITERIA (Quoted Product/ Item Wise)-Drugs/Medicine</b> |  |
| 1   | The quoted item section must fall into the valid GMP certificate / satisfactory GMP inspection report.   |
| 2   | Valid Drug Registration Certificate of quoted item for quoted pack size/ volume/ strength issued by DRAP.  |
| 3   | At least One-year experience of quoted item of manufacturer from date of registration.   |
| 4   | Tested samples of the quoted item declared Substandard (if any) by the DTLs of Punjab (Not over 5%) from 01.01.2025 till the closing date of documents submission.   |
| 5   | <p>The bidder (s) must have the finished dosage form production capacity of quoted product (s) (including equipment, personnel, processes and storage etc.) at least 3 times annually of the advertised quantity in 12-hour shift, whereas, 24 hours for IV Infusions only.</p> <p>The bidder will submit duly filled &amp; signed proforma for the quoted sections along with all details of equipment, personnel, processes and storage etc.</p> <p>Practical production capacity of quoted item (s) cumulatively may be evaluated/ verified after audit/ assessment submitted documentation and inspection. All equipment make; model and serial no. must be specified (Proforma is available in this document as a ready reference).</p> <p>Any missing information regarding equipment, personnel, processes, storage and misleading information will lead to disqualification of the bidder.</p> |
| 6   | The bidder shall submit the maximum batch size of quoted item in units. The bidder shall also submit data of number of batches (quoted item) produced since January 2025 on its letter head. Physical evaluation of data may be done to review the performance of the bidder (s) and protocols compliance.   |
| 7   | Substandard/ Adulterated/ Spurious Batch of quoted item Recall compliance report as per regulatory timeline since (01.01.2025) if any.   |
| 8   | Any Punitive Action Taken by DRAP since (01.01.2025).<br>(Punitive means, suspension/ cancelation of Manufacturing License or Drug Registration by DRAP from (01.01.2025) till the closing date of documents submission.)  |
| 9   | Any Punitive Action Taken by PQCB since (01.01.2025). (Punitive means,   |

|    |  |
|----|--|
|    | Prosecuted by PQCB).   |
| 10 | The bidder shall provide a complete method of testing of finished drug (where manufacturer's/Innovator's specifications approved by DRAP).   |
| 11 | The bidder shall have primary reference standard or secondary reference standard from ISO/ IEC 17034 compliant source of the quoted item (s) along with Certificate of Analysis (COA). The trail of the standard should be verifiable from the source/ manufacturer. In case of working standard, it must be traceable/standardized to primary standard. The bidder shall submit availability of documentary evidence with the bid.<br>In case traceability of reference standard is not available through pharmacopeial source, then available standard must be traceable with the innovator. |
| 12 | The bidder shall declare the source of active pharmaceutical ingredient (API) being utilized to produce quoted items as per regulatory requirement / approval. The successful bidder shall provide import trail (for imported source) of API along with invoice at the time of supply of medicine (s).   |
| 13 | The bidder shall submit real time/accelerated stability studies data of quoted item. Accelerated stability studies data will be accepted only in cases where the product registration period is less than the shelf-life period.   |

### **MARKING CRITERIA FOR LOCAL MANUFACTURER (DRUGS/ MEDICINES)**

| <b>SR</b>   | <b>MARKING CRITERIA 2026-27</b>   | <b>CATEGORY POINTS</b> |
|---|---|------------------------|
| <b>1</b>  | <b>QUALIFICATION/ ACCREDITATION OF BIDDER</b>   | <b>MAX 10</b>          |
| i.  | Valid ISO 14001   | 2                      |
| ii.   | Valid ISO 9001  | 2                      |
| iii.  | Valid ISO 45001/ 18001  | 2                      |
| iv.   | Valid ISO/ IEC 17025  | 2                      |
| v.  | WHO/PICs/MHRA   | 2                      |
| The authenticity of the certificate (ISO) shall be verified online by issuing authority. Online verification shall be accepted only. ISO Certificate issuing organization/ authority must be approved from Pakistan National Accreditation Council (PNAC) / United Kingdom Accreditation Service (UKAS) / International Accreditation Forum (IAF) / International Accreditation Service (IAS). The authenticity of WHO/PICs/MHRA shall be verified from their official websites/DRAP (PICs/MHRA). |   |                        |
| <b>2</b>  | <b>RELEVANT EXPERIENCE AND PAST PERFORMANCE OF BIDDER &amp; QUOTED PRODUCT</b>  | <b>MAX 10</b>          |
| i.  | Experience of bidder in supply of Public Health Sector Goods for at least three years. The bidder shall submit a purchase order (before 01 July 2023) & Delivery Challan/payment proof for stock receiving against PO issued by public health sector institution. No marks shall be awarded where a bidder has experience for less than 3 years i.e., before 01 July 2023.  | 02                     |
| ii.   | Experience of sales of quoted products in public sector institutions since 01.01.2025. Bidder should provide any three purchase orders of the quoted items from public sector institutions of Punjab. The Bidder shall submit Delivery Challan/payment proof for stock receiving along with standard DTL report against each PO. 01 mark will be awarded for each Delivery Challan/Payment proof & subsequent DTL report. | 03                     |
| iii.  | Experience of sales of quoted products in the private sector since 01-07-2024. The bidder shall provide IQVIA data of the quoted item as evidence to substantiate its claim. The quantity of the quoted product   | 05                     |

|   |   |               |
|---|---|---------------|
|   | presented on IQVIA should be at least ten percent (10 %) of the advertised quantity to claim the marks. Those which are not registered with IQVIA shall present quoted product sales with batch details record. Such data shall be provided on the letter head of the bidder indicating the issuance to authorized distributor/chain pharmacy. Moreover, such bidders shall also provide sale data reflected in FBR portal to claim the marks and evidence of FBR portal must be submitted. Procuring Agency may verify records during the physical inspection of the bidder/premises/point of sales. |               |
| <b>3 A</b>  | <b>PLANT/ EQUIPMENT CAPABILITY (OTHER THAN IV INFUSIONS)</b>  | <b>MAX 20</b> |
| i.  | 04 No. of functional & calibrated HPLC system CFR 21 part 11 compliant with UV/ PDA Detector (2 mark will be awarded for each functional system).   | 8             |
| ii.   | 01 No. of functional & calibrated Gas Chromatography (Mass Spectroscopy/ Flame Ionization Detector) System CFR 21 part 11 compliant with updated library <b>or</b> functional & calibrated LCMS system CFR 21 part 11 compliant   | 4             |
| iii.  | 01 No. of functional & calibrated Fourier Transform Infrared Spectroscopy system CFR 21 part 11 compliant   | 2             |
| iv.   | 02 No. of functional & calibrated climatic chamber for storage of reference standard. One mark will be awarded for each functional system.  | 2             |
| v.  | 01 No. of functional & calibrated 05 digit/ decimal weighing balance  | 2             |
| vi.   | 02 No. of functional Dissolution Apparatus CFR 21 part 11 compliant coupled with HPLC/UV (where applicable). One mark will be awarded for each functional system. Dosage forms whereby Dissolution Apparatus is not required, these marks will also be awarded to bidder fully complying point no. I of this parameter.   | 2             |
| <b>3 B</b>  | <b>PLANT/ EQUIPMENT CAPABILITY (FOR LARGE VOLUME IV INFUSIONS e.g NORMAL SALINE, RINGER LACTATE, DEXTROSE, FLUID GELATIN, MANNITOL OR ANY COMBINATION)</b>  | <b>MAX 17</b> |
| i.  | 02 No. of functional & calibrated HPLC system CFR 21 part 11 compliant with UV/ PDA Detector (2 mark will be awarded for each functional system).   | 4             |
| ii.   | 01 No. of functional & calibrated Atomic Absorption System CFR 21 part 11 compliant   | 4             |
| iii.  | 01 No. of functional & calibrated Flame Photometer CFR 21 part 11 compliant.  | 3             |
| iv.   | 01 No. of functional & calibrated Liquid Particle Counter system CFR 21 part 11 compliant   | 3             |
| v.  | 01 No. of functional & calibrated Osmo-meter  | 2             |
| vi.   | 01 No. of functional & calibrated Potentiometer   | 1             |
| The bidder will provide the details of make, model & serial no. of the equipment along with year of purchase. The equipment must be operational & calibrated and must have an active audit trail. |   |               |
| <b>4</b>  | <b>PERSONNEL CAPABILITY</b>   | <b>MAX 05</b> |
| i.  | At least one qualified personnel by Pakistan National Accreditation Council/ UKAS/IAF/IAS on ISO/ IEC 17025 having at least three years of pharmaceutical laboratory experience.  | 02            |
| ii.   | At least one person who has M Phill or higher degree in Analytical/ Pharmaceutical Chemistry / Pharmaceutics with 10 years' quality control experience OR PharmD/B. Pharm with 12 years' experience.  | 02            |

|   |  |                |
|---|--|----------------|
| iii.  | At least one M Phill or higher degree in any Discipline of Pharmacy with 05 years' production experience.  | 01             |
| ISO Certificate issuing organization/ authority must be approved from Pakistan National Accreditation Council (PNAC) / United Kingdom Accreditation Service (UKAS) / International Accreditation Forum (IAF) / International Accreditation Service (IAS). The bidder shall provide the attested copies of the degree, certificate and appointment letter issued by bidder to employees. The bidder shall also undertake that the staff (claimed in Bidding documents) is currently working at Manufacturing Unit. |  |                |
| <b>5</b>  | <b>FINANCIAL POSITION/ CAPABILITY</b>  | <b>MAX. 20</b> |
| i.  | The bidder has financial capability equivalent to the total estimated cost of the quoted products.<br>e.g., If a bidder is quoting a single item and the estimated cost of that item is Rs.100 million and the bidder financial capability is equivalent to PKR.100 million or higher, then ten marks will be awarded. Similarly, if a bidder participates in five items and the total advertised estimated cost is PKR.200 million. Ten (10) marks shall be awarded if the bidder has financial capability of PKR.200 million or higher. Hence, the bidder must be careful about selecting/ quoting of item.<br>Note: if the bidder quotes item(s) having estimated cost more than the required financial worth of the firm, no marks shall be awarded in this parameter.       | 10             |
| ii.   | The bidder has financial capability 1.5 times the total estimated cost of the quoted products.<br>e.g., If a bidder is quoting a single item and the estimated cost of that item is Rs.100 million and the bidder's financial capability is equivalent to PKR.150 million or higher, then fifteen marks will be awarded. Similarly, if a bidder participates in five items and the total advertised estimated cost is PKR.200 million. Fifteen (15) marks shall be awarded if the bidder has financial capability of PKR.300 million or higher. Hence, the bidder must be careful about selecting/ quoting of item.<br>Note: if the bidder quotes item(s) having estimated cost more than the required financial worth of the firm, no marks shall be awarded in this parameter. | 15             |
| iii.  | The bidder has financial capability two times the total estimated cost of the quoted products.<br>e.g., If a bidder is quoting a single item and the estimated cost of that item is Rs.100 million and the bidder's financial capability is equivalent to PKR.200 million or higher, then twenty marks will be awarded. Similarly, if a bidder participates in five items and the total advertised estimated cost is PKR.200 million. Twenty (20) marks shall be awarded if the bidder has financial capability of PKR.400 million or higher. Hence, the bidder must be careful about selecting/ quoting of item.<br>Note: if the bidder quotes item(s) having estimated cost more than the required financial worth of the firm, no marks shall be awarded in this parameter.   | 20             |
| Financial position/ capability will be assessed by average annual financial turnover for any three financial years (i.e. 2021-22/2022-23/2023-24/2024-25)/calendar year (i.e. 2022/2023 /2024/2025). Bidder shall provide FBR income tax return/sales Tax return for the financial year 2021-22/2022-23/2023-24/2024-25 or in case of calendar year 2022/2023/2024/2025. Note: (Joint venture, consortium and subsidiary shall not be accepted.)  |  |                |

| 6   | SOURCE OF API OF QUOTED ITEM  | MAX 02    |
|---|---|-----------|
| i.  | Source Licensed by Original or accredited by FDA/WHO/EMA (Certificate).<br>The bidder shall quote the source. Moreover, the bidder shall provide a copy of the Bill of Lading/Airway Bill along with GD documents etc. as evidence of Active Pharmaceutical Ingredient import from the quoted source to claim the marks. The originator will be awarded full marks. | 02        |
| ii.   | Raw material from National Source (where available & quoted).   | 01        |
| The bidder shall provide import documents (Bill of Lading/Airway Bill along with GDs etc.) of quoted source at the time of delivery of goods (for serial # i). Furthermore, the bidder shall undertake that supplier product shall be manufactured from API of quoted source. |   |           |
| <b>DRUGS/MEDICINES OTHER THAN IV INFUSION QUALIFYING MARKS = 40 (60%)</b>   |   | <b>67</b> |
| <b>FOR LARGE VOLUME IV INFUSIONS QUALIFYING MARKS = 38 (60%)</b>  |   | <b>64</b> |

The procuring Agency may inspect the premises of the bidder (s) for physical evaluation/ verification of claims and all documentary evidence submitted by the bidder. Any false/ fabricated information/documents/ data will lead to disqualification of the bidder. Financial bids of only “Technically Responsive Bidders” shall be opened.

**B- BIDDER AS SOLE AGENTS OF FOREIGN PRINCIPAL (DRUGS/MEDICINES)  
KNOCK DOWN CRITERIA (FIRM WISE)**

| <b>SR BIDDING DOCUMENTS PARAMETERS 2026-27</b>                                |  |
|---|--|
| 1   | Valid Drugs Sale License issued by Competent Authority for Sole Agents of Foreign Principal.   |
| 2   | Valid Sole Agency Agreement.   |
| 3   | The bidder will submit Original 0.5 % Bid security of estimated cost of each item having validity of at least 180 days in favor of Directorate General Health Services Punjab in the shape of Bank Guarantee/CDR/ Pay Order/ Bank Draft/ Banker's cheque must be submitted physically at Purchase Cell, Directorate General Health Services Punjab, 24-Cooper Road Lahore on or before <b>31-03-2026</b> till <b>11:00 A.M.</b>  |
| 4   | The bidder must submit bio similarity studies data of quoted item (for biological and biotech products). The biosimilar products should submit biosimilar study from DRAP notified labs or WHO/ JPMHLW/ EMA/ US FDA approved/accredited labs only OR quoted product must have status of reference product for biosimilar studies on USA FDA/ registered at EMA official websites.  |
| 5   | Two packs of samples (Samples must be of commercial pack). Specifications quoted in the technical offer will be verified from samples provided versus product registration certificate. Products that comply 100% with the required specifications and fulfill the requirements as per labeling & packing rules shall be considered.   |
| 6   | Valid GMP Certificate issued by Drug Regulatory Authority of Country of Manufacturer/ Certificate of Pharmaceutical Product (COPP) of Manufacturer.  |
| 7   | The bidder should have a valid NTN, GST, Active Taxpayer Status verifiable from FBR website.   |
| 8   | The bidder shall undertake applicable e-stamp paper of PKR.300 issued by Government of Punjab regarding: <ul style="list-style-type: none"> <li>i. That bidder is currently not blacklisted/ debarred by Directorate General Health Services (DGHS) Punjab/ PPRA.</li> <li>ii. That the Information provided by the bidder is in accordance with the terms &amp; conditions of the document.</li> <li>iii. That bidder (Sole agent) follows Good Distribution and Storage Practices as per requirements. The bidder must mention address of storage facility of bidder.</li> <li>iv. That none of its supplied sample (s) of quoted section has been declared Spurious/ Adulterated from any DTL of Punjab since 01.01.2023 till the closing date of documents submission. The claim of the bidder shall be verified from PQCB, Punjab by the procuring agency.</li> <li>v. That the bidder accepts all the terms and conditions of the documents.</li> <li>vi. The bidder shall be bound to supply the stock in compliance with SRO 470(I)/2017 subject to requirement of the department.</li> <li>vii. The bidder shall be bound to supply packaging material for medicines and medical devices in accordance with the approved sample of commercial pack</li> </ul> |
| 9   | Affidavit as per bid form 2  |
| <b>2-KNOCK DOWN CRITERIA (QUOTED PRODUCT/ITEM WISE)- DRUGS/MEDICINE ITEMS</b> |  |
| 1   | Valid Drug Registration Certificate of quoted item for quoted pack size/volume/ strength issued by DRAP.   |
| 2   | At least One-year experience of quoted item from the date of registration.   |
| 3   | Quality Compliance Standards (EMA/ JpMHLW/ US FDA/ prequalified by WHO (Certificate) of quoted item. (Exempted for plasma expanders)   |
| 4   | Required storage temperature as per product's requirement.   |

|   |   |
|---|---|
| 5 | Tested samples of the quoted item declared Substandard by the DTLs of Punjab (Not over 5%) from (01.01.2025) if any.  |
| 6 | Substandard/ Adulterated/ Spurious Batch of quoted item Recall compliance report as per regulatory timeline since (01.01.2025) if any.  |
| 7 | Any Punitive Action Taken by DRAP since (01.01.2025). (Punitive means, suspension/ cancelation of Manufacturing License or Drug Registration by DRAP from (01.01.2025) till the closing date of Document submission). |
| 8 | Any Punitive Action Taken by PQCB since (01.01.2025). (Punitive means, Prosecuted by PQCB).   |

### **MARKING CRITERIA FOR BIDDER AS SOLE AGENTS**

| SR  | MARKING CRITERIA 26-27  | CATEGORY POINTS |
|---|---|-----------------|
| <b>1</b>  | <b>Qualification/ Accreditation of Bidder</b>   | <b>MAX 2</b>    |
| i.  | Valid ISO 9001  | 2               |
| The authenticity of the certificate (ISO) shall be verified online by issuing authority. Online verification shall be accepted only. ISO Certificate issuing organization/ authority must be approved from Pakistan National Accreditation Council (PNAC)/ United Kingdom Accreditation Service (UKAS)/ International Accreditation Forum (IAF)/ International Accreditation Service (IAS). |   |                 |
| <b>2</b>  | <b>RELEVANT EXPERIENCE AND PAST PERFORMANCE OF THE BIDDER/ QUOTED PRODUCT</b>   | <b>MAX 10</b>   |
| i.  | Experience of bidder in supply of Public Health Sector Goods for at least three years. The bidder shall submit a purchase order (before 01 July 2023) & Delivery Challan/payment proof for stock receiving against PO issued by public health sector institution. No marks shall be awarded where a bidder has experience for less than 3 years i.e., before 01 July 2023.  | 02              |
| ii.   | Experience of sales of quoted products in public sector institutions since 01.01.2025. Bidder should provide any three purchase orders of the quoted items from public sector institutions of Punjab. The Bidder shall submit Delivery Challan/payment proof for stock receiving along with standard DTL report against each PO. 01 mark will be awarded for each Delivery Challan/Payment proof & subsequent DTL report.   | 05              |
| iii.  | Experience of sales of quoted products in the private sector since 01.07.2024. The bidder shall provide IQVIA data of the quoted item as evidence to substantiate its claim. The quantity of the quoted product presented on IQVIA should be at least ten percent (10 %) of the advertised quantity to claim the marks. Those which are not registered with IQVIA shall present quoted product sales with batch details record. Such data shall be provided on the letter head of the bidder indicating the issuance to authorized distributor/chain pharmacy. Moreover, such bidders shall also provide sale data reflected in FBR portal to claim the marks and evidence of FBR portal must be submitted. Procuring Agency may verify records during the physical inspection of the bidder/premises/point of sales. | 03              |
| <b>3</b>  | <b>BIDDER &amp; MANUFACTURER RELATIONSHIP REGARDING IMPORT EXPERIENCE (IN CASE OF SOLE AGENT)</b>   | <b>MAX 10</b>   |
| i.  | Upto 2 years  | 05              |
| ii.   | Above 2 to 5 years  | 08              |
| iii.  | Above 5 years   | 10              |
| The bidder will provide the relevant authorization certificate (s) in this regard.  |   |                 |

|  |  |                |
|--|--|----------------|
| <b>4</b>   | <b>EQUIPMENT, PERSONNEL, PROCESSES &amp; STORAGE FACILITY</b>  | <b>MAX 10</b>  |
| i.   | ERP/ SAP System or in-house-built E-System to ensure track & traceability of the products, purchases & inventory management.   | <b>5</b>       |
| ii.  | Warehousing/ Storage Availability as per the quantity/ requirement of the product. Facility must be supported by Drugs Sale License.   | <b>5</b>       |
| <b>5</b>   | <b>FINANCIAL POSITION/ CAPABILITY</b>  | <b>MAX. 20</b> |
|  | The bidder has financial capability equivalent to the total estimated cost of the quoted products.<br>e.g., If a bidder is quoting a single item and the estimated cost of that item is Rs.100 million and the bidder financial capability is equivalent to PKR.100 million or higher, then ten marks will be awarded. Similarly, if a bidder participates in five items and the total advertised estimated cost is PKR.200 million. Ten (10) marks shall be awarded if the bidder has financial capability of PKR.200 million or higher. Hence, the bidder must be careful about selecting/ quoting of item.<br>Note: if the bidder quotes item(s) having estimated cost more than the required financial worth of the firm, no marks shall be awarded in this parameter.       | 10             |
|  | The bidder has financial capability 1.5 times the total estimated cost of the quoted products.<br>e.g., If a bidder is quoting a single item and the estimated cost of that item is Rs.100 million and the bidder's financial capability is equivalent to PKR.150 million or higher, then fifteen marks will be awarded. Similarly, if a bidder participates in five items and the total advertised estimated cost is PKR.200 million. Fifteen (15) marks shall be awarded if the bidder has financial capability of PKR.300 million or higher. Hence, the bidder must be careful about selecting/ quoting of item.<br>Note: if the bidder quotes item(s) having estimated cost more than the required financial worth of the firm, no marks shall be awarded in this parameter. | 15             |
|  | The bidder has financial capability two times the total estimated cost of the quoted products.<br>e.g., If a bidder is quoting a single item and the estimated cost of that item is Rs.100 million and the bidder's financial capability is equivalent to PKR.200 million or higher, then twenty marks will be awarded. Similarly, if a bidder participates in five items and the total advertised estimated cost is PKR.200 million. Twenty (20) marks shall be awarded if the bidder has financial capability of PKR.400 million or higher. Hence, the bidder must be careful about selecting/ quoting of item.<br>Note: if the bidder quotes item(s) having estimated cost more than the required financial worth of the firm, no marks shall be awarded in this parameter.   | 20             |
| Financial position/ capability will be assessed by average annual financial turnover for any three financial years (i.e. 2021-22/2022-23/2023-24/2024-25)/calendar year (i.e. 2022/2023/ 2024/ 2025). Bidder shall provide FBR income tax return/sales Tax return for the financial year 2021-22/2022-23/2023-24/2024-25 or in case of calendar year 2022/2023 /2024/2025. Note: (Joint venture, consortium and subsidiary shall not be accepted.) |  |                |
| <b>QUALIFYING MARKS = 32</b>   |  | <b>52</b>      |

The procuring Agency may inspect the premises of the bidder (s) for physical evaluation/ verification of claims and all documentary evidence submitted by the bidder. Any false/ fabricated information/ documents/ data will lead to

disqualification of the bidder.

**QUALIFYING MARKS: 32 OUT OF 52**

**Financial bids of only “Technically Responsive Bidders” shall be opened.**

**Section V**  
**Bid Form**

# BID COVER SHEET

Bid Ref. Tender:-----

Date: -----

Name of the Supplier/Firm Contractor: \_\_\_\_\_

\_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_

E-mail: \_\_\_\_\_ Phone: \_\_\_\_\_ Facsimile: \_\_\_\_\_

Bid for:

Selected Items from the Schedule of Requirements:

| <i><b>Tender Enquiry/<br/>Item No.</b></i> | <i><b>Name of the tendered Item</b></i> | <i><b>Brand name quoted</b></i> | <i><b>Drug Registration Number<br/>(attach certificate)</b></i> | <i><b>Specifications</b></i> | <i><b>Name of API manufacturer &amp; country of origin</b></i> |
|--|---|---------------------------------|---|------------------------------|--|
| <b>1</b>                                   |   |                                 |   |                              |  |
| <b>2</b>                                   |   |                                 |   |                              |  |
| <b>3</b>                                   |   |                                 |   |                              |  |
| <b>4</b>                                   |   |                                 |   |                              |  |
| <b>5</b>                                   |   |                                 |   |                              |  |
| <b>6</b>                                   |   |                                 |   |                              |  |
| <b>7</b>                                   |   |                                 |   |                              |  |

Signed:

Dated:

Official Stamp:

## BID FORM 1

# Letter of Intention

*Bid Ref No.*

*Date of the Opening of Bids*

*Name of the Firm: {Add name e.g., Supply of Drugs/Medicines}*

To: *[Name and address of Procuring Agency]*

Dear Sir/Madam,

Having examined the bidding documents including Addenda Nos. *[insert numbers & Date of individual Addendum]*, the receipt of which is hereby acknowledged, we, the undersigned, offer to supply and deliver the Goods under the above-named Contract in full conformity with the said bidding documents and at the rates/unit prices described in the price schedule or such other sums as may be determined in accordance with the terms and conditions of the Contract. The amounts are in accordance with the Price Schedules attached herewith and are made part of this bid.

We undertake, we have no reservation to these Bidding Documents, if our bid is accepted, to deliver the Goods in accordance with the delivery schedule specified in the schedule of requirements.

If our bid is accepted, we undertake to provide a performance security/guaranty in the form, in the amounts, and within the times specified in the bidding documents.

We agree to abide by this bid, for the Bid Validity Period specified in the Bid Data Sheet and it shall remain binding upon us and may be accepted by you at any time before the expiration of that period.

Until the formal final Contract is prepared and executed between us, this bid, together with your written acceptance of the bid and your notification of award, shall constitute a binding Contract between us.

We understand that you are not bound to accept the lowest or any bid you may receive.

We undertake that, in competing for (and, if the award is made to us, in executing) the above contract, we will strictly observe the laws against fraud and corruption in force in Pakistan.

We confirm that we comply with the eligibility requirements as per ITB clauses 18 & 19 of the bidding documents.

Dated this *[insert number]* day of *[insert month]*, *[insert: year]*.

Signed:

In the capacity of *[insert title or position]*

Duly authorized to sign this bid for and on behalf of *[insert name of Bidder]*

## BID FORM 2

# AFFIDAVIT

(Stamp paper Rs.300/-)

I/We, the undersigned solemnly state that:

- 1) I/We have read the contents of the Bidding Documents, have fully understood it and accept all terms and conditions as mentioned in this document.
- 2) The Bid being submitted by the undersigned complies with the requirements enunciated in the bidding documents.
- 3) The Goods that we propose to supply under this contract are eligible goods within the meaning of Clause 18 of the ITB.
- 4) The undersigned are also eligible Bidders within the meaning of Clause 19 of the ITB.
- 5) The undersigned are solvent and competent to undertake the subject Contract under the Laws of Pakistan.
- 6) The undersigned have not paid nor have agreed to pay, any Commissions or Gratuities to any official or agent related to this bid or award or contract.
- 7) The undersigned are not blacklisted or facing debarment from DGHS, Punjab.
- 8) That the prices offered are not more than trade price.
- 9) I/We further undertake that I/we will be ready to pay the standard charges/fee of testing samples by DTLs Punjab.
- 10) I/we further undertake to provide the Batch Release Laboratory Test Reports of each batch of the product on its delivery.
- 11) I/we further undertake that the supplies against the purchase orders during financial year 2026-27 issued by this procuring agency or by DHAs or projects/programs/attach departments has been made within 120 days of the issuance of purchase order(s). Partial quantities supplied are also considered.

I /We affirm that the contents of this affidavit are correct to the best of our knowledge and belief.

Signed In the capacity of ***[insert title or position]***  
Duly authorized to sign this bid/affidavit for and on behalf of ***[insert name of Bidder]***

**BID FORM 3**

**MANUFACTURER'S SOLE AUTHORIZATION<sup>1</sup>**

**To: *[Name & Address of the Procuring Agency]***

WHEREAS *[name of the Manufacturer]* who are established and reputable Manufacturers of *[name and/or description of the goods]* having factories at *[address of factory]* do hereby solely authorize *[name and address of Supplier/ Agent]* to submit a bid, and subsequently negotiate and sign the Contract with you against the Invitation for Bids (IFB) No. *[Reference of the Invitation to Bid]* for the goods manufactured by us.

We hereby extend our full guarantee and warranty as per Clause 14 &15 of the General Conditions of Contract for the goods offered for supply by the above firm against this Invitation for Bids.

**Signature:** \_\_\_\_\_

**Designation:** \_\_\_\_\_

**Official Stamp:** \_\_\_\_\_

---

<sup>1</sup>This letter of authority should be on the letterhead of the Manufacturer and should be signed by a person competent and having the power of attorney to bind the Manufacturer. It should be included by the Bidder in its

# Price Schedule

**User Note:** *This form is to be filled in by the Bidder for quoted items/products and shall submit with Financial Proposal. If intended to quote for more than one item/product, a separate form should be used for each item/product intended to quote for.*

Name of the Firm: \_\_\_\_\_

Bid Reference. No: \_\_\_\_\_

Date of opening of Bid: \_\_\_\_\_

| Sr. No.      | Name of the tender Item | Quoted Brand | Unit Price (inclusive all applicable taxes if any + transportation charges) | No. of Units | Total Price | Discounts (if any) | Final Total Price (Inclusive of all taxes if any) |
|--------------|-------------------------|--------------|---|--------------|-------------|--------------------|---|
| 1            | 2                       | 3            | 4   | 5            | 6           | 7                  | 8   |
|              |                         |              |   |              | 4*5         |                    | 6-7   |
| <b>TOTAL</b> |                         |              |   |              |             |                    |   |

A) Final Total Price: \_\_\_\_\_

B) Discount: \_\_\_\_\_

C) Final Quoted Price: \_\_\_\_\_

**(C=A-B)**

**Signature:** \_\_\_\_\_

**Designation:** \_\_\_\_\_

**Date:** \_\_\_\_\_

**Official Stamp:** \_\_\_\_\_

<sup>2</sup> If a Bidder does not wish to offer an item wise discount but intends to offer an overall discount to its quoted price that should be mentioned here.

**BID FORM 5**

# Performance Guarantee

To: *[Name & Address of the Procuring Agency]*

Whereas *[Name of Supplier]* (hereinafter called "the Supplier") has undertaken, in pursuance of Contract No. *[Number]* dated *[date]* to supply *[description of goods]* (hereinafter called "the Contract").

And whereas it has been stipulated by you in the said Contract that the Supplier shall furnish you with a Bank Guarantee by a scheduled bank for the sum of **04%** of the total Contract amount as a Security for compliance with the Supplier's performance obligations in accordance with the Contract.

And whereas we have agreed to give the Supplier a Guarantee:

Therefore, we hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, up to a total of *[Amount of the Guarantee in Words and Figures]* and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the Contract and without cavil or argument, any sum or sums within the limits of *[Amount of Guarantee]* as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until the \_\_\_\_\_ day of \_\_\_\_\_, 202\_\_\_\_\_

Signature and Seal of the Guarantors/ Bank

Address

Date

**Section VI**  
**DRAFT STANDARD**  
**CONTRACT**

# Contract Form AGREEMENT

**THIS Framework CONTRACT** is made at on \_\_\_\_\_ day of 202.., between the \_\_\_\_\_, (hereinafter referred to as the “Purchaser”) of the First Part; and M/s (*firm name*) a firm registered under the laws of Pakistan and having its registered office at (*address of the firm*) (hereinafter called the “Supplier”) of the Second Part (hereinafter referred to individually as “Party” and collectively as the “Parties”).

**WHEREAS** the Purchaser invited bids for procurement of goods, in pursuance whereof M/s (*firm name*) being the Manufacturer/ authorized sole agent of (item name) in Pakistan and ancillary services offered to supply the required item (s); and  
Whereas, the Purchaser has accepted the bid by the Supplier as per following detail.

| Item No. | Item Name | Approved Specifications | Unit Price in PKR/<br>quoted Currency<br>(As per contract) | Quantity | Total Cost<br>(PKR/quoted<br>Currency) |
|----------|-----------|-------------------------|--|----------|--|
|          |           |                         |  |          |  |
|          |           |                         |  |          |  |

**NOW THE PARTIES TO THIS CONTRACT AGREE TO THE FOLLOWING.**

1. **The Contract:** The following documents shall be deemed to form and be read and construed as integral part of this Contract, viz: -
  - a. This Contract Form
  - b. The Schedule of Requirements **Annex- A**
  - c. Special Conditions of Contract & the Technical Specifications **Annex- B**
  - d. Original Price Schedule along with unsolicited discount offered by the firm (if any) submitted by the Bidder. **Annex-C**
  - e. The Notification of Award (AAT) **Annex-D**
  - f. Purchase Order **Annex-E**
  - g. Payment Schedule **Annex-F**
  - h. The General Conditions of Contract **Annex-G**
  - i. Performance Guarantee/ Security **Annex-H**
  - j. Manufacturer’s certificate of warranty under Drugs Act 1976/DRAP Act 2012 & rules framed thereunder **Annex-I**
  - k. The bidding document of Procuring Agency **Annex-J**
  - l. Integrity Pact **Annex-H**
2. **Interpretation:** In this Contract words and expressions shall have the same meanings as are respectively assigned to them in the General Conditions of this Contract hereinafter referred to as “Contract”:
3. **The Term of the Contract:** This contract shall remain valid for one year from the date of signing, unless amended by mutual consent.
4. The Supplier declares as under:
  - i. [*Name of the Supplier*] hereby declares that it has not obtained or induced the procurement of any Contract, right, interest, privilege or other obligation or benefit from Government of Punjab or any administrative subdivision or agency thereof or any other entity owned or controlled by it (Government of Punjab) through any corrupt business practice.
  - ii. Without limiting the generality of the foregoing, [the Seller/ Supplier] represents and warrants that it has fully declared the brokerage, commission, fees etc., paid or payable to anyone and not given or agreed to give and shall not give

or agree to give to anyone within or outside Pakistan either directly or indirectly through any natural or juridical person, including its affiliate, agent, associate, broker, consultant, director, promoter, shareholder, sponsor or subsidiary, any commission, gratification, bribe, finder's fee or kickback, whether described as consultation fee or otherwise, with the object of obtaining or including the procurement of a Contract, right interest, privilege or other obligation or benefit in whatsoever form from Government of Punjab, except that which has been expressly declared pursuant hereto.

- iii. *[The Supplier]* certifies that has made and shall make full disclosure of all agreements and arrangements with all persons in respect of or related to the transaction with Government of Punjab and has not taken any action or shall not take any action to circumvent the above declaration, representation or warranty.
- iv. *[The Supplier]* accepts full responsibility and strict liability for making any false declaration, not making full disclosure, misrepresenting facts or taking any action likely to defeat the purpose of this declaration, representation and warranty. It agrees that any Contract, right, interest, privilege or other obligation or benefit obtained or procured as aforesaid shall, without prejudice to any other right and remedies available to Procuring Agency under any law, Contract or other instrument, be voidable at the option of Procuring Agency.
- v. Notwithstanding any rights and remedies exercised by Procuring Agency in this regard, *[The Supplier]* agrees to indemnify Procuring Agency for any loss or damage incurred by it on account of its corrupt business practices and further pay compensation to Procuring Agency in an amount equivalent to ten times the sum of any commission, gratification, bribe, finder's fee or kickback given by *[The Supplier]* as aforesaid for the purpose of obtaining or inducing the procurement of any Contract, right, interest, privilege or other obligation or benefit in whatsoever form from Procuring Agency.
- vi. In case of any dispute concerning the interpretation and/or application of this Contract shall be settled through arbitration mutually agreed by both parties/ Additional Chief Secretary or his nominee. The decisions taken and/or award made by the sole arbitrator shall be final and binding on the Parties.

**5. Items to be Supplied & Agreed Unit Cost:**

- (i) The Supplier shall provide to the Purchaser the items on the agreed cost more specifically described in the Price Schedule Submitted by the Bidder (Annex C).
- (ii) Each Item supplied shall strictly conform to the Schedule of Requirements (Annex A) and to the Technical Specification (Annex B) prescribed by the Purchaser against each item
- (iii) The Unit Cost agreed in the Price Schedule (Annex C), is inclusive of all taxation and costs associated with transportation and other agreed incidental costs.

**6. Payments:** The Purchaser hereby covenants to pay the Supplier in consideration of the provision of the Goods and Services, as specified in the Schedule of Requirements and Technical Specification in accordance with the Price Schedule submitted by the Supplier, the amount against the delivered items or such other sum as may become payable under the provisions of this Contract at the time and in the manner prescribed by this Contract.

**7. Mode of Payment:** All payments to the Supplier shall be made through Crossed Cheques issued in the name of [supplier's name] in case of DDP.

**Payment Schedule:** All payments to the Supplier shall be made in accordance with the agreed Payment Schedule at Annex: F, upon satisfactory completion of delivery

and fulfillment of documentary and codal formalities highlighted in the Payment Schedule at Annex F.

**8. Performance Guarantee/Security:**

- (i) The Supplier, within 10 days of signing of this contract, shall provide to the Purchaser a Performance Security in the form of an Irrevocable Bank Guarantee equivalent to 04% of the total Contract amount having validity of one year from its date of issuance from any scheduled bank on the prescribed format and in prescribed manner. This Performance Guarantee/Security shall be released to the Supplier upon successful completion of the Contract.
- (ii) Failure to submit a Performance Guarantee/Security shall result into cancellation of contract & blacklisting of firm.

**9. Penalties/ Liquidated Damages**

- (i) Wherein the Supplier fails to make deliveries as per signed contract & purchase order and within the stipulated time frame specified in the Schedule of Requirement, the Contract to the extent of non-delivered portion of supplies shall stand cancelled.
- (ii) After the cancellation of the Contract no supplies shall be accepted and the amount of Performance Guaranty/Security to the extent of non-delivered portion of supplies shall be forfeited.
- (iii) If the Supplier fails to supply the whole consignment, within the contract period, and not able to deliver to consignee's end, the entire amount of Performance Guaranty/Security shall be forfeited to the Government account and the firm shall be blacklisted minimum for two years for future participation.
- (iv) The exact time frame for making supplies with and without penalty shall be indicated in subsequent contract/purchase order.
- (v) In case of late delivery of goods beyond the periods specified in the Schedule of Requirements and after issuance of subsequent contract/purchase order by the consignee, a penalty @ 0.067% per day of the cost of late delivered supply shall be imposed upon the Supplier, maximum up to 10 %.

**10. Notices:** All notices and correspondences incidental to this contract shall be in English language and shall be addressed to:

**For the Purchaser:** \_\_\_\_\_  
\_\_\_\_\_

**For the Supplier:** \_\_\_\_\_  
\_\_\_\_\_

IN WITNESS Whereof the Parties hereto have caused this Contract to be executed at \_\_\_\_\_(The place) and shall enter into force on the day, month and year first above mentioned.

**Signed/ Sealed: For the Manufacturer/  
Authorized Agent.**

**Sealed & Signed on behalf of Purchaser**

**Witnesses-1 on behalf of the Contractor**

**Witnesses-1 on behalf of the Purchaser**

**Witnesses-2 on behalf of the Contractor**

**Witnesses-2 on behalf of the Purchaser**

C.C :

1. \_\_\_\_\_

2. \_\_\_\_\_

## Annex-A

### Schedule of Requirements

The supplies shall be delivered in accordance with the Contract/Purchase Orders issued by Director General Health Services Punjab / procuring agency(ies),

*Respective Consignee's End:*

- I. **DGHS/ VERTICAL PROGRAMS/ PHFMC, ETC Designated warehouse situated in Lahore, Multan or any other place.**
- II. **DISTRICTS HEALTH AUTHORITIES - designated place of concerned district (s) in Punjab.**

**Free delivery to Consignee's end (DDP) basis.**

| Supply schedule   | Delivery days   |                                  |               |      |   |    |                                 |   |    |                                 |   |    |                                  |
|---|---|----------------------------------|---------------|------|---|----|---------------------------------|---|----|---------------------------------|---|----|----------------------------------|
| 100% of the ordered quantity from the date of issuance of Contract/Purchase Order<br><b>Without penalty</b> | <p style="text-align: center;">120 Days</p> <p>Procuring agency shall issue purchase order as per signed framework contract with minimum following timelines of supply. However, procuring agency may adjust framework / timelines as per its requirement in collaboration with successful bidder.</p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th style="text-align: center;">Sr.</th> <th style="text-align: center;">% of delivery</th> <th style="text-align: center;">days</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">1</td> <td style="text-align: center;">40</td> <td style="text-align: center;">Till or before 60<sup>th</sup></td> </tr> <tr> <td style="text-align: center;">2</td> <td style="text-align: center;">30</td> <td style="text-align: center;">Till or before 90<sup>th</sup></td> </tr> <tr> <td style="text-align: center;">3</td> <td style="text-align: center;">30</td> <td style="text-align: center;">Till or before 120<sup>th</sup></td> </tr> </tbody> </table> <p>Note: The total maximum delivery period shall remain 120 days.</p> | Sr.                              | % of delivery | days | 1 | 40 | Till or before 60 <sup>th</sup> | 2 | 30 | Till or before 90 <sup>th</sup> | 3 | 30 | Till or before 120 <sup>th</sup> |
| Sr.   | % of delivery   | days                             |               |      |   |    |                                 |   |    |                                 |   |    |                                  |
| 1   | 40  | Till or before 60 <sup>th</sup>  |               |      |   |    |                                 |   |    |                                 |   |    |                                  |
| 2   | 30  | Till or before 90 <sup>th</sup>  |               |      |   |    |                                 |   |    |                                 |   |    |                                  |
| 3   | 30  | Till or before 120 <sup>th</sup> |               |      |   |    |                                 |   |    |                                 |   |    |                                  |
| With penalty @ 0.067 % per day  | After Completion of due delivery period specified against each installment penalty @ 0.067 % per day shall be imposed within contract period, maximum up to 10%.  |                                  |               |      |   |    |                                 |   |    |                                 |   |    |                                  |

## **Special Conditions of the Contract** **& Technical Specifications**

a). **Product Specifications.**

*(Detailed technical specifications, given in Award of Contract, will be followed)*

b). **Labeling and Packing**

- i. The manufacturer shall follow the Drugs (Labelling and Packing) Rules 1986, framed under the Drugs Act, 1976.
- ii. However, the name of Drug / Medicine (Generic & Brand), equally prominent, should be printed/ written in indelible ink both in English and Urdu on the outer cartons and on each Pack, Bottle, Strip/ Blister, Tubes etc. Besides the name and principal place of business of the Manufacturer, the drug manufacturing license no., manufacturing date, expiry date, registration No., batch No., retail price, and Urdu version namely: name of drug, dosage and instructions, should also be written on the outer carton and on the most inner container in bold letters. All tablets shall be supplied in strip / blister pack (one side aluminum and other side PVC/PVD). Expiry date must be printed on each strip / blister. The syrup should be supplied in glass / pet bottle with sealed caps.
- iii. The condition of green packing is relaxed for drugs imported in finished form, but the supplier will be instructed to print/stamp/affix a sticker as per requirement of individual item *(after considering the condition of storage of each item)*.
- iv. The quality of packing material, its labelling, packing structure and printing will be same as that of their commercial supply but according to government supply color scheme.

c) Firm shall assure that the grammage of packaging material of supplied Drugs/ medicines as per submitted commercial pack at the time of bid submission.

d) **Additional instructions for packing**

- i. The suppliers are required to furnish the Warranty certificate with regard to the potency and stability (Including coloration of medicines) of the Drug/Medicine for human consumption etc. in accordance with the Drugs Act 1976, DRAP Act 2012, Punjab Drugs (Amendments) Act 2017 & rules framed thereunder on notarized stamp paper of Rs.300/-
- ii. 2-D Data Matrix Bar code is compulsory (for Local Manufacturers) to be placed at unit carton of supplies to be received at MSD/Sub-MSD of DGHS / or any other place in district Punjab as per regulatory requirement. Procuring agency(ies) shall issue their purchase order & place of delivery will be as per there in any district of the Punjab.
- iii. The bidder shall supply the Drugs/Medicines/Items in special green packing with Logo of the Government of Punjab (exempted for imported items). The following wording/insignia shall be printed in bold letters both in Urdu & English in indelible red color ink on each carton, pack, bottle, strip / blister, tubes, vial / ampoule etc. In combo Packs the sterilized water for injection / solvent shall bear the wording/insignia on the vial/ampoules etc.  

**“PUNJAB GOVERNMENT PROPERTY”**  
**“NOT FOR SALE”**
- iv. After signing of the Contract, the Supplier shall submit the samples of finished medicines in accordance with the above instructions for approval of label. All subsequent supplies must be in accordance with the approved samples.

- v. The Artwork of final packaging/label will be approved by the committee notified by procuring agency.

d). **Shelf life**

- i. The shelf life must be up to **85% for the locally manufactured drugs** and **75% for the imported drugs**.
- ii. The lower limit of the shelf life must be up to **80% and 70% with imposition of 1% penalty** charges of actual shortfall in shelf life below prescribed limit for locally manufactured and imported medicines respectively.
- iii. In case of *vaccines & other biotechnical products*, the stores with the **shelf life up to 70%** will be accepted without penalty charges and **up to 60%** with imposition of **1% penalty** charges of actual shortfall in shelf life below prescribed limit”

e). **Testing/Verification Procedures**

- i. After delivery of drugs and medicines at the Purchaser's premises, the Consignee shall send the samples from **all batches of each consignment** of the supplied store to the Drugs Testing Laboratory, Punjab, for testing. The Inspection Committee constituted by the Purchaser shall inspect the quantity, specifications of goods after receipt of standard quality report of each batch of supplied store issued by DTL concerned under Drugs Act 1976/DRAP Act 2012/ Punjab Drugs (Amendments) Act 2017 & rules framed thereunder. The concerned drug inspector shall submit certificate of analysis, chromatogram, and/ dissolution report to the DTLs along with samples. **The cost of the lab tests** shall be borne by the Supplier. **The firm shall be bound to provide primary reference standard (s)/traceable secondary standard (s) to the concerned Drugs Testing Laboratories of Punjab as and when demanded. In case of secondary reference standard, the certificate of analysis and proof of traceability shall also be provided by the contractor.**
- ii. In case of **Adverse/ failure** report of any batch, the Supplier will be intimated and they will be bound to re-supply the **entire fresh stock** of that batch **free of cost** within the reasonable time period to be intimated by the purchaser but not later than **21 days (three weeks)** from the date of intimation, which will be subject to completion of all testing and verification formalities. The case will be dealt as per Drugs Act 1976/DRAP Act 2012/Punjab Drugs (Amendments) Act 2017 and disposal of substandard stocks.
- iii. The contracting firm shall provide following documents along with supply:
- Certificate of Analysis duly signed
  - Good Declaration Certificate for imported Active Pharmaceutical Ingredient. In case, the contractor fails to provide evidence as per quoted source (FDA/WHO/EMA as claimed in the offer), the supplier will be liable for the deduction of penalty equivalent to 10% of the total value of the supplied stock subject to fulfilment of all other terms and conditions of the bidding documents/contract.
  - Chromatogram of CFR 21 Part -11 Compliant System having active audit trail (Official method/ DRAP approved method)
  - Dissolution report as per applicable method (where applicable)
- iv. The Procuring Agency may conduct pre-shipment or post-shipment Inspection of manufacturing site for verification of production & quality control compliances to the extent of contracted product.
- v. The Inspection Committee will carry out detailed physical examination of stocks and can reject, even if it is declared of standard quality by DTL, if found not according to the approved sample and other technical specifications like packaging, labeling, printing and quantity etc. Moreover, the inspection committee may reject the stock in case of non-production of above mention stocks even if

product has been declared standard quality from DTL. Furthermore, the Supplier will also be responsible to replace the unconsumed expired stores without any further charges.

f) **Transportation/Delivery Requirements**

- i. The Supplier shall arrange such transportation of the drugs and medicines as is required to prevent their damage or deterioration during transit to their destination and in accordance with the terms and manner prescribed in the Schedule of Requirement. The goods shall be delivered through reputable courier service having following features to ensure quality, quantity, safety & efficacy of supplied medicines & surgical disposable items:
  - a. Traceable online dispatch and delivery record
  - b. Dispatch facilities as per labeled requirements of medicines like maintenance of temperature, humidity etc. of the supplies
- ii. All costs associated with the transportation including loading/unloading of drugs and medicines and road taxes shall be borne by the Supplier.
- iii. All **cold chain (perishable)** items must be delivered in a safe and proper manner, prescribed for such types of items.
- iv. The firm will be bound to provide stocks in reefer container(s) for delivery of goods to the procuring agencies. Physical assurance will be pre-requisite at the time of delivery of goods.

g) **Integrity Pact**

The Supplier shall provide affidavit of integrity pact for awarded item/items with contract value equal to or more than 10 million Rupees on the prescribed format on stamp paper of Value Rs:300/- as per Annexure-H.

Annex-C

**PRICE SCHEDULE SUBMITTED BY THE  
BIDDER**

*(The approved price schedule submitted by the Bidder will be attached)*

Annex-D

**NOTIFICATION OF AWARD/ ADVANCE ACCEPTANCE OF  
TENDER**

Annex-E

**PURCHASE ORDER**

## **PAYMENT SCHEDULE**

- i. *100% Payment to the Suppliers will be made by the concerned Purchaser/Disbursing & Drawing Officer (DDO).*
  - a. *against satisfactory performance and upon submission of required documents and in accordance with the procedure mentioned in Rule 64 and other relevant rules of PPR-2014.*
  - b. *on production of Inspection Certificate, certificate of analysis, chromatogram (where applicable) dissolution report (where applicable) and receipt certificate from Consignee, after recovery of Government dues (if any) including Professional Tax and DTL Testing Charges.*
- ii. *Part Supply as per given delivery schedule and Part Payment is allowed as per contract/purchase order.*

## Annex- G

# General Conditions of Contract (GCC)

- 1. Definitions**
- 1.1 In this Contract, the following terms shall be interpreted as indicated:
- (a) "The Contract" means the agreement entered into between the Purchaser (DGHS) and the Supplier, as recorded in the Agreement signed by the Parties, including all attachments and appendices thereto and all documents incorporated by reference therein.
  - (b) "The Contract Price" means the price payable to the Supplier under the Contract for the full and proper performance of its Contractual obligations.
  - (c) "The Goods" means all those supplies which the Supplier is required to supply to the Purchaser under the Contract.
  - (d) "The Services" means those services ancillary to the supply of above goods, such as printing of special instructions on the label and packing, design and logo of the Government of Punjab, transportation of goods up to the desired destinations and other such obligations of the Supplier covered under the Contract.
  - (e) "GCC" means the General Conditions of Contract contained in this section.
  - (f) "SCC" means Special Conditions of the Contract.
  - (g) "The Purchaser" means the Government of Punjab, District Health Authority, *itself*.
  - (h) "The Supplier" means the individual or firm supplying the goods under this Contract.
  - (i) "Day" means calendar day.
- 2. Application**
- 2.1 These General Conditions shall apply to the extent that they are not superseded by provisions of other parts of the Contract.
- 3. Source of Import**
- 3.1 All goods and related services to be supplied under the contract that are required to be imported in Pakistan shall have their origin in eligible source countries as prescribed by the commercial policies of the Federal Government of Pakistan and all expenditures made under the contract shall be limited to such goods and services.
- 3.2 For purposes of this clause, "origin" means the place where the goods are produced, or the place from which the related services are supplied. Goods are produced when, through manufacturing or processing.
- 4. Standards**
- 4.1 The goods supplied under this Contract shall conform to the standards mentioned in the Technical Specifications.
- 4.2 In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide the Goods and Services and to remedy defects therein in conformity in all respects with the provisions of this Contract.

- 4.3 If the Supplier provide substandard item and fail to provide the fresh supply, the payment of risk purchase (which will be purchased by the Purchaser) the price difference shall be paid by the Supplier.
- 4.4 In case of supply of substandard product the cost associated with disposal/destruction or associated handling shall be borne by the Supplier i.e., removal from purchaser's premises, burning, dumping, or incineration.
- 5. Use of Contract Documents and Information.**
- 5.1 The Supplier shall not, without the Purchaser's prior written consent, disclose the Contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the Purchaser in connection therewith, to any person other than a person employed by the Supplier in the performance of the Contract. Disclosure to any such employed person shall be made in confidence and shall extend only so far as may be necessary for purposes of such performance.
- 5.2 The Supplier shall not, without the Purchaser's prior written consent, make use of any document or information enumerated in GCC Clause 5.1 except for purposes of performing the Contract.
- 5.3 Any document, other than the Contract itself, enumerated in GCC Clause 5.1 shall remain the property of the Purchaser and shall be returned (all copies) to the Purchaser on completion of the Supplier's performance under the Contract if so, required by the Purchaser.
- 5.4 The Supplier shall permit the Purchaser to inspect the Supplier's accounts and records relating to the performance of the Supplier.
- 6. Patent Rights**
- 6.1 The Supplier shall indemnify the Purchaser against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof in the country.
- 7. Submission of Samples**
- 7.1 Before commencing supplies, the Supplier shall provide samples free of cost, if and as specified in the Schedule of Requirements of the product to the designated office or staff, as the case may be.
- 8. Ensuring storage arrangements**
- 8.1 To ensure storage arrangements for the intended supplies, the Supplier shall inform the Purchaser at least One (01) week in advance. However, in case no space is available at the Purchaser's premises at the time of supply, the Purchaser shall, at least 02 days prior to such situation, shall inform the Supplier, in writing, of the possible time frame of availability of space by which the supplies can be made. In case the Supplier abides by the given time frame it shall not be penalized for delay.
- 9. Inspections and Tests**
- 9.1 The Purchaser or its representative shall have the right to inspect (pre-shipment inspection or post-shipment inspection) and / or to test the goods in accordance with the procedure given in the SCC to confirm their conformity to the Contract specifications at no extra cost to the Purchaser.

- 9.2 The Purchaser's right to inspect, test and, where necessary, reject the goods after the goods either at Supplier's premises or upon arrival at Purchaser's destinations shall in no way be limited or waived by reason of the goods having previously been inspected, tested, and passed by the Purchaser or its representative prior to the goods delivery from the point of Supply or manufacturing.  
Nothing in GCC Clause 9 shall in any way release the Supplier from any warranty or other obligations under this Contract.
- 10. Delivery and Documents**
- 10.1 The Supplier in accordance with the terms and manner specified in the Schedule of Requirements shall make delivery of the goods.
- 10.2 The Supplier shall furnish all necessary documentation necessary for completion of the delivery, at the time of delivery and in the manner prescribed.
- 10.3 The goods supplied under the Contract shall be delivered on free delivery of consignee's end basis under which risk is transferred to the buyer after the Goods having been delivered;
- 11. Insurance**
- 11.1 The supplier shall be solely responsible for Insurance of the Goods subject to the contract.
- 12. Transportation**
- 12.1 The Supplier shall arrange such transportation of the goods as is required to prevent their damage or deterioration during transit to their final destination and in accordance with the terms and manner prescribed in the Schedule of Requirement/bidding document.
- 12.2 All costs associated with the transportation of the goods subject to this contract shall be borne by the Supplier.
- 13. Incidental Services**
- 13.1 The Supplier shall be required to provide the incidental services as specified in the SCC and the cost of which is included in the total bid price.
- 14. Warranty**
- 14.1 All goods subject to this contract shall be accompanied by the necessary warranty in the manner prescribed in the SCC.
- 14.2 The Purchaser shall promptly notify the Supplier in writing of any claims arising under this warranty.
- 15. Payment**
- 15.1 The purchaser shall make payments to the Supplier in accordance with the conditions set forth in the Payment Schedule agreed and annexed to this contract.
- 15.2 The currency of payment shall be Pakistan Rupees in case of DDP.
- 16. Prices**
- 16.1 Prices charged by the Supplier for goods delivered under the Contract shall not vary from the prices quoted by the Supplier in its bid and shall remain the same till the expiry of the contract unless the Parties to this contract mutually agree to vary the prices.
- 17. Contract Amendments**
- 17.1 No variation in or modification of the terms of the Contract shall be made except by written amendment signed by the Parties.
- 18. Assignment**
- 18.1 The Supplier shall not assign, in whole or in part, its obligations to perform under this Contract, except with the Purchaser's prior written consent.
- 19. Subcontracts**
- 19.1 The Supplier shall not be allowed to sublet and award

**20. Delays in the Supplier's Performance**

- subcontracts under this Contract.
- 20.1 Delivery of the goods shall be made by the Supplier in accordance with the time schedule prescribed by the Purchaser in the Schedule of Requirements.
- 20.2 If at any time during performance of the Contract, the Supplier encounters conditions impeding timely delivery of the goods, the Supplier shall promptly notify the Purchaser in writing of the fact of the delay, its likely duration and its cause(s). As soon as practicable after receipt of the Supplier's notice, the Purchaser shall evaluate the situation and may at its discretion extend the Supplier's time for performance, with liquidated damages, in which case the extension shall be ratified by the Parties by an amendment to the Contract.
- 20.3 Except as provided under GCC Clause 20, a delay by the Supplier in the performance of its delivery obligations shall render the Supplier liable to the imposition of liquidated damages as prescribed in the SCC, unless the parties to this contract mutually agree for extension of time.

**21. Termination for Default**

- 21.1 The Purchaser, without prejudice to any other remedy for breach of Contract, by written notice of default sent to the Supplier, may terminate this Contract in whole or in part:
- (a) if the Supplier fails to deliver any or all installments of the goods within the period(s) specified in the signed contract, and subsequent contract/Purchase order or within any extension thereof granted by the Purchaser pursuant to GCC Clause 20; or
  - (b) if the Supplier fails to perform any other obligation(s) under the Contract.
  - (c) if the Supplier, in the judgment of the Purchaser has engaged in corrupt or fraudulent practices in competing for or in executing the Contract.
- For the purpose of this clause Corrupt and fraudulent practices means:
- "the offering, giving, receiving, or soliciting of anything of value to influence the action of a public official or the contractor in the procurement process or in contract execution to the detriment of the procuring agency; or misrepresentation of facts in order to influence a procurement process or the execution of a contract, collusive practices among bidders (prior to or after bid submission) designed to establish bid prices at artificial, non-competitive levels and to deprive the procuring agency of the benefits of free and open competition and any request for, or solicitation of anything of value by any public official in the course of the exercise of his duty; it may include any of the following practices:*
- (i) *coercive practice by impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence the actions of a party to achieve a wrongful gain or to cause a wrongful loss to another party.*

- (ii) *collusive practice by arrangement between two or more parties to the procurement process or contract execution, designed to achieve with or without the knowledge of the procuring agency to establish prices at artificial, noncompetitive levels for any wrongful gain.*
- (iii) *corrupt practice by offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence the acts of another party for wrongful gain.*
- (iv) *fraudulent practice by any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation.*
- (v) *obstructive practice by harming or threatening to harm, directly or indirectly, persons or their property to influence their participation in a procurement process, or affect the execution of a contract or deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements before investigators in order to materially impede an investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation, or acts intended to materially impede the exercise of inspection and audit rights;*

**Corrupt or Fraudulent Practices and Mechanism to Debar/Blacklist the Defaulted Bidder.**

21.2 The following are the events which would lead to initiate under Rule 21 of PPRA Rules 2014 Blacklisting / Debarment process.

- i. Submission of false fabricated/ forged documents for procurement in tender.
- ii. Not attaining required quality of work.
- iii. Inordinate tardiness in accomplishment of assigned/agreed responsibilities / contractual obligations resulting loss to procuring agency / Government.
- iv. Non execution of work as per terms & condition of contract.
- v. Any unethical or unlawful professional or business behavior detrimental to good conduct and integrity of the public procurement process.
- vi. Involvement in any sort of tender fixing.
- vii. Persistent and intentional violation of important conditions of contract
- viii. Non-adherence to quality specification despite being importunately pointed out.
- ix. Security consideration of the State i.e., any action that jeopardizes the security of the State or good repute of the procuring agency.

**PROCEDURE:** As per Rule-21 of the Punjab Procurement Rules 2014.

**22. Force Majeure**

- 22.1 Notwithstanding the provisions of GCC Clauses 20 and 21, the Supplier shall not be liable for forfeiture of its Performance Guaranty, or termination/blacklisting for default if and to the extent that its delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure. For the purposes of this clause Force Majeure means an act of God or an event beyond the control of the Supplier and not involving the Supplier's fault or negligence directly or indirectly purporting to mis-planning, mismanagement and/or lack of foresight to handle the situation. Such events may include but are not restricted to acts of the Purchaser in its sovereign capacity, wars or revolutions, fires, floods, earthquakes, strikes, epidemics, quarantine restrictions and freight embargoes.
- 22.2 If a Force Majeure situation arises, the Supplier shall promptly notify the Purchaser in writing with sufficient and valid evidence of such condition and the cause thereof. The Purchaser shall examine the merits of the case and all reasonable alternative means for completion of the purchase order under the signed contract and inform the Supplier of its findings promptly.
- 22.3 Unless Purchaser informs the Supplier in writing of its agreement on the application of force majeure, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical and shall seek reasonable alternative means for performance not prevented by the Force Majeure event.

**23. Termination for Insolvency**

- 23.1 The Purchaser may at any time terminate the Contract by giving written notice of one-month time to the Supplier if the Supplier becomes bankrupt or otherwise insolvent. In this event, termination shall be without compensation to the Supplier, provided that such termination shall not prejudice or affect any right of action or remedy which has accrued or shall accrue thereafter to the Parties.

**24. Arbitration and Resolution of Disputes**

- 24.1 The Purchaser and the Supplier shall make every effort to resolve amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the Contract.
- 24.2 If, after thirty (30) days from the commencement of such informal negotiations, the Purchaser and the Supplier have been unable to resolve amicably a Contract dispute, either party may require that the dispute be referred to the Arbitrator for resolution through arbitration.
- 24.3 In case of any dispute concerning the interpretation and/or application of this Contract shall be settled through arbitration under the Arbitration Act of 1940 (As amended from time to time).

**25. Governing Language**

- 25.1 The Contract shall be written in English language. Subject to GCC Clause 26, the version of the Contract written in the

specified language shall govern its interpretation. All correspondence and other documents pertaining to the Contract, which are exchanged by the Parties, shall be written in English.

- 26. Applicable Law** 26.1 This Contract shall be governed by the Laws of Pakistan and the courts of Pakistan shall have exclusive jurisdiction.
- 27. Notices** 27.1 Any Notice given by one party to the other pursuant to this Contract shall be sent to the other party in writing and on the others address specified in SCC.  
27.2 A notice shall be effective when delivered or on the notice's effective date, whichever is later.
- 28. Taxation** 28.1 All taxation, whether International, Federal, Provincial or Local, shall be borne by the Supplier.
- 29. Blacklisting mechanism** 29.1 The procuring agency may, on information received from any resource, issue show cause notice to a bidder or contractor.  
29.2 The show cause notice shall contain:  
(a) precise allegation, against the bidder or contractor.  
(b) the maximum period for which the procuring agency proposes to debar the bidder or contractor from participating in any public procurement of the procuring agency; and  
(c) the statement, if needed, about the intention of the procuring agency to make a request to the Authority for debarring the bidder or contractor from participating in public procurements of all the procuring agencies.  
29.3 The procuring agency shall give minimum of seven days to bidder or contractor for submission of written reply of the show cause notice.  
29.4 In case, the bidder or contractor fails to submit written reply within the requisite time, the procuring agency may issue notice for personal hearing to the bidder or contractor/ authorize representative of the bidder or contractor and the procuring agency shall decide the matter on the basis of available record and personal hearing, if availed.  
29.5 In case the bidder or contractor submits written reply of the show cause notice, the procuring agency may decide to file the matter or direct issuance of a notice to the bidder or contractor for personal hearing.  
29.6 The procuring agency shall give minimum days (as per authority decision) to the bidder or contractor for appearance before the specified officer of the procuring agency for personal hearing.  
29.7 The procuring agency shall decide the matter on the basis of the available record and personal hearing of the bidder or contractor, if availed.  
29.8 The procuring agency shall decide the matter within fifteen days from the date of personal hearing unless the personal hearing is adjourned to a next date and in such an eventuality, the period of personal hearing shall be reckoned from the last date of personal hearing.  
29.9 The procuring agency shall communicate to the bidder or contractor the order of debarring the bidder or contractor from

participating in any public procurement with a statement that the bidder or contractor may, within thirty days, prefer a representation against the order before the Managing Director of the Authority.

- 29.10 The procuring agency shall, as soon as possible, communicate the order of blacklisting to the Authority with the request to upload the information on its website.
- 29.11 If the procuring agency wants the Authority to debar the bidder or contractor from participating in any public procurement of all procuring agencies, the procuring agency shall specify reasons for such dispensation.
- 29.12 The Authority shall immediately publish the information and decision of blacklisting on its website.
- 29.13 In case of request of a procuring agency under para 11 or representation of any aggrieved person under rule 21, the Managing Director shall issue a notice for personal hearing to the parties and call for record of proceedings of blacklisting. The parties may file written statements and documents in support of their contentions.
- 29.14 In case of representation of any aggrieved person or procuring agency under rule 21, the Chairperson shall issue a notice for personal hearing to the parties and may call for the record of the proceedings. The parties may file written statements and documents in support of their contentions.
- 29.15 In every order of blacklisting under rule 21, the procuring agency shall record reasons of blacklisting and also reasons for short, long or medium period of blacklisting.
- 29.16 The Authority shall upload all the decisions under rule 21, available with it, on its website. But the name of a bidder or contractor shall immediately be removed from the list of blacklisted persons on expiry of period of blacklisting or order of the competent authority to that effect, whichever is earlier.
- 29.17 An effort shall be made for electronic communication of all the notices and other documents pursuant to this mechanism or process.

Annex-H

# **INTEGRITY PACT**

AFFIDAVIT (Rs: 300/- Stamp Paper)

We (Name of the bidder / supplier) being the first duly sworn on oath submit, that Mr./ Ms. (if participating through agent / representative) is the agent/ representative duly authorized by (Name of the bidder company) hereinafter called the Contractor to submit the attached bid to the (Name of the Purchaser). Affiant further states that the said M/s (Bidding Firm/Company Name) has not paid, given or donate or agreed to pay, given or donate to any line officer or employee of the (Name of the Purchaser) any money or thing of value, either directly or indirectly, for special consideration in the letting of the contract, or for giving undue advantage to any of the bidder in the bidding and in the evaluation and selection of the bidder for contract or for refraining from properly and thoroughly maintaining projects implementations, reporting violation of the contract specification or other forms of non-compliance.

Signature & Stamp

Subscribed and sworn to me this \_\_\_\_\_ day of \_\_\_\_ 20 \_\_\_\_\_ Notary  
Public

## PRODUCTION CAPACITY PERFORMA

PRODUCTION CAPACITY OF M/S. \_\_\_\_\_

(Each quoted Section Capacity will be submitted separately dully filled & signed on the letter head of the bidder)

### General Information

|                              |                   |
|------------------------------|-------------------|
| Dosage Form/ Sections Quoted | i. Tablet (e.g.,) |
|------------------------------|-------------------|

The details of capacity calculations are as under:

### SECTION WISE MANUFACTURING CAPACITY

1. CAPACITY OF \_\_\_\_\_ SECTION (name of first section)

### NUMBER OF PRODUCTS MANUFACTURED BY THE FIRM

| Section        | No of products registered for self-manufacturing | No of products registered for contract manufacturing | Total |
|----------------|--|--|-------|
| 1. Tablet      |  |  |       |
| 2. Capsule     |  |  |       |
| 3. Injection   |  |  |       |
| Total products |  |  |       |

| Step wise capacity of _____ manufacturing | Maximum production Capacity (_____)                                     |                                   |
|---|---|-----------------------------------|
|   | Per day<br>(12 except infusions /24 (for infusions) hour working shift) | Per month<br>(_____ working days) |
|   |   |                                   |
|   |   |                                   |
|   |   |                                   |
|   |   |                                   |

| Quarter Wise capacity utilized in _____ Section          |                           |                  |                          |
|--|---------------------------|------------------|--------------------------|
| Quarter  | Actual Production (_____) | Capacity (_____) | Capacity utilized in (%) |
| I (1 <sup>st</sup> Jan – 31 <sup>st</sup> March _____)   |                           |                  |                          |
| II (1 <sup>st</sup> April – 30 <sup>th</sup> June _____) |                           |                  |                          |
| III (1 <sup>st</sup> July – 30 <sup>th</sup> Sep _____)  |                           |                  |                          |
| IV (1 <sup>st</sup> Oct – 31 <sup>st</sup> Dec _____)    |                           |                  |                          |
| Average Capacity Utilized for January – December _____   |                           |                  |                          |

**Manufacturing Capacity Utilized (average):** \_\_\_\_\_

**Manufacturing Capacity Available (average):** \_\_\_\_\_

### CAPACITY OF QUALITY CONTROL DEPARTMENT

| Quality Control Equipment Detail |           |      |                   |                          |
|----------------------------------|-----------|------|-------------------|--------------------------|
| Sr. No                           | Equipment | Qty. | Functional Status | Capacity per day (tests) |
| 1                                |           |      |                   |                          |
| 2                                |           |      |                   |                          |
| 3                                |           |      |                   |                          |

|   |  |  |  |  |
|---|--|--|--|--|
| 4 |  |  |  |  |
| 5 |  |  |  |  |

The details of the total registered products of the firm with respect to the method of testing is provided below:

| Total No of registered Products | No of Products with official Monograph (USP/BP/JP) | No of Products with In-house/Innovator specs | No of product currently on HPLC |
|---------------------------------|--|--|---------------------------------|
|                                 |  |  |                                 |

| HPLC Capacity Calculation Quarter Wise<br>(Average _____ tests/day/HPLC) |                                    |                    |               |                 |             |                       |
|--|------------------------------------|--------------------|---------------|-----------------|-------------|-----------------------|
| TOTAL  |                                    |                    | HPLC          |                 |             |                       |
| Quarter  | Average testing capacity / Quarter | Raw material tests | Product tests | Stability tests | Total tests | Capacity utilized (%) |
| I (1 <sup>st</sup> Jan – 31 <sup>st</sup> March _____)                   |                                    |                    |               |                 |             |                       |
| II (1 <sup>st</sup> April – 30 <sup>th</sup> June _____)                 |                                    |                    |               |                 |             |                       |
| III (1 <sup>st</sup> July – 30 <sup>th</sup> Sep _____)                  |                                    |                    |               |                 |             |                       |
| IV (1 <sup>st</sup> Oct – 31 <sup>st</sup> Dec _____)                    |                                    |                    |               |                 |             |                       |
| <b>Average capacity</b>  |                                    |                    |               |                 |             |                       |

HPLC Testing Capacity Utilized (average): \_\_\_\_\_  
HPLC Testing Capacity Available (average): \_\_\_\_\_

| UV Spectrophotometer Capacity Calculation Quarter Wise<br>(Average _____ tests/day) |                                    |                    |                             |                 |             |                       |
|---|------------------------------------|--------------------|-----------------------------|-----------------|-------------|-----------------------|
| TOTAL   |                                    |                    | UV                          |                 |             |                       |
| Quarter   | Average testing capacity / Quarter | Raw material tests | Product tests (Dissolution) | Stability tests | Total tests | Capacity utilized (%) |
| I (1 <sup>st</sup> Jan – 31 <sup>st</sup> March _____)                              |                                    |                    |                             |                 |             |                       |
| II (1 <sup>st</sup> April – 30 <sup>th</sup> June _____)                            |                                    |                    |                             |                 |             |                       |
| III (1 <sup>st</sup> July – 30 <sup>th</sup> Sep _____)                             |                                    |                    |                             |                 |             |                       |
| IV (1 <sup>st</sup> Oct – 31 <sup>st</sup> Dec _____)                               |                                    |                    |                             |                 |             |                       |
| <b>Average capacity</b>   |                                    |                    |                             |                 |             |                       |

UV Testing Capacity Utilized (average): \_\_\_\_\_  
UV Testing Capacity Available (average): \_\_\_\_\_

**Dissolution Capacity Calculation Quarter Wise**

(Average \_\_\_\_\_ tests/day)

**TOTAL DISSOLUTION**

| Quarter  | Average capacity / Quarter | Raw material tests | Product tests | Stability tests | Total tests | Capacity utilized (%) |
|--|----------------------------|--------------------|---------------|-----------------|-------------|-----------------------|
| I (1 <sup>st</sup> Jan – 31 <sup>st</sup> March _____)   |                            |                    |               |                 |             |                       |
| II (1 <sup>st</sup> April – 30 <sup>th</sup> June _____) |                            |                    |               |                 |             |                       |
| III (1 <sup>st</sup> July – 30 <sup>th</sup> Sep _____)  |                            |                    |               |                 |             |                       |
| IV (1 <sup>st</sup> Oct – 31 <sup>st</sup> Dec _____)    |                            |                    |               |                 |             |                       |
| <b>Average capacity</b>                                  |                            |                    |               |                 |             |                       |

Dissolution Testing Capacity Utilized (average): \_\_\_\_\_

Dissolution Testing Capacity Available (average): \_\_\_\_\_

**Sterility Testing Capacity Calculation Quarter Wise**

(Average \_\_\_\_\_ tests/day)

| Quarter  | Average capacity/ Quarter | Test Performed | Capacity Utilized % |
|--|---------------------------|----------------|---------------------|
| I (1 <sup>st</sup> Jan – 31 <sup>st</sup> March _____)   |                           |                |                     |
| II (1 <sup>st</sup> April – 30 <sup>th</sup> June _____) |                           |                |                     |
| III (1 <sup>st</sup> July – 30 <sup>th</sup> Sep _____)  |                           |                |                     |
| IV (1 <sup>st</sup> Oct – 31 <sup>st</sup> Dec _____)    |                           |                |                     |
| <b>Average capacity available:</b>                       |                           |                |                     |

Sterility Testing Capacity Utilized (average): \_\_\_\_\_

Sterility Testing Capacity Available (average): \_\_\_\_\_

**Bacterial Endotoxin Test Capacity Calculation Quarter Wise**

(Average \_\_\_\_\_ tests / day)

| Quarter  | Average capacity/ Quarter | Test Performed | Capacity Utilized % |
|--|---------------------------|----------------|---------------------|
| I (1 <sup>st</sup> Jan – 31 <sup>st</sup> March _____)   |                           |                |                     |
| II (1 <sup>st</sup> April – 30 <sup>th</sup> June _____) |                           |                |                     |
| III (1 <sup>st</sup> July – 30 <sup>th</sup> Sep _____)  |                           |                |                     |
| IV (1 <sup>st</sup> Oct – 31 <sup>st</sup> Dec _____)    |                           |                |                     |

**Average capacity available:** \_\_\_\_\_

**BET Testing Capacity Utilized (average):** \_\_\_\_\_  
**BET Testing Capacity Available (average):** \_\_\_\_\_

**Hot and Cold Incubator Testing Capacity**

The testing capacity of hot and cold incubators was determined at maximum production load during the study period i.e. January – December \_\_\_\_\_.

| <b>HOT INCUBATOR</b>  |  |   |                              |                               |
|-----------------------|--|---|------------------------------|-------------------------------|
| <b>Item</b>           | <b>Media capacity at a time for incubation</b> | <b>Media used for testing (Maximum production load)</b> | <b>Capacity utilized (%)</b> | <b>Capacity Available (%)</b> |
| <b>Test</b>           |  |   |                              |                               |
| Media bottles         |  |   |                              |                               |
| Media plates          |  |   |                              |                               |
| <b>Pre Incubated</b>  |  |   |                              |                               |
| <b>Item</b>           | <b>Maximum capacity</b>                        | <b>Maximum incubated</b>                                | <b>Capacity utilized (%)</b> | <b>Capacity Available (%)</b> |
| Media bottles         |  |   |                              |                               |
| Media plates          |  |   |                              |                               |
| <b>COLD INCUBATOR</b> |  |   |                              |                               |
| <b>Item</b>           | <b>Media capacity at a time for incubation</b> | <b>Media used for testing (Maximum production load)</b> | <b>Capacity utilized (%)</b> | <b>Capacity Available (%)</b> |
| <b>Test</b>           |  |   |                              |                               |
| Media bottles         |  |   |                              |                               |
| Media plates          |  |   |                              |                               |
| <b>Pre Incubated</b>  |  |   |                              |                               |
| <b>Item</b>           | <b>Maximum capacity</b>                        | <b>Maximum incubated</b>                                | <b>Capacity utilized (%)</b> | <b>Capacity Available (%)</b> |
| Media bottles         |  |   |                              |                               |
| Media plates          |  |   |                              |                               |

**CAPACITY OF STORAGE AREA**

- a. Raw Material \_\_\_\_\_
- b. In process quarantine \_\_\_\_\_
- c. Finished Goods \_\_\_\_\_
- d. Packing Material \_\_\_\_\_

**All submitted information must be correct. Any false claim will lead to disqualification of bidder. The Inspection Panel may evaluate the claim of the bidder for its verification.**

**ANNEXURES:**

- Annexure 1** • List of all production batches of each quoted product manufactured from January 2025 to December 2025.

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr | Generic Name  | Specifications  | Est. Rate | DHAs      | DGHS      | Clinic on Wheel | PHFMC   | Grand Total | Value of Bid Security |
|----|---|---|-----------|-----------|-----------|-----------------|---------|-------------|-----------------------|
| 1  | Acetylsalicylic acid 300mg Tab/ Cap                   | Acetylsalicylic Acid 300mg Tablet, Aluminum strip pack, pack of 600 or less packed in carton.   | 2.20      | -         | 3,000,000 |                 | 40,000  | 3,040,000   | 33,440                |
| 2  | Acyclovir 500mg Infusion                              | Acyclovir 500mg powder in Vial Inj./Inf. Pack of 10 or less, Packed in Carton with leaflet  | 301.00    | -         | 17,000    |                 | 660     | 17,660      | 26,578                |
| 3  | Amikacin (Sulfate) 250mg Injection                    | Amikacin (as Sulphate) 250mg per 2ml Injection, Vial/Ampoule. Pack of 10 or less. Packed in carton with leaflet.  | 68.00     | 477,001   |           |                 | 11,700  | 488,701     | 166,158               |
| 4  | Amiodarone HCl 150mg Injection                        | Amiodarone HCl 150mg/3ml Injection, ampoule of 3ml, pack of 10's or less, packed in carton with leaflet.  | 250.00    | -         | 50,000    |                 | 380     | 50,380      | 62,975                |
| 5  | Amoxicillin + Clavulanic Acid 1.2g Injection          | Amoxicillin 1gm (as Sodium) + Clavulanic Acid 200mg (as Potassium) Injection Vial, pack of 10 or less with solvent & leaflet.   | 166.00    | 272,446   | 200,000   |                 | 11,400  | 483,846     | 401,593               |
| 6  | Atracurium (besylate) 10mg/ml Injection               | Atracurium (besylate) Injection 10mg/ml. Ampoule of 2.5ml/3ml, pack of 10 ampoules or less, packed in carton with leaflet. The firm will produce batch-wise cold chain data from the source of origin & thermo-log data from factory to warehouse as well as colour coding to distinguish from distilled water. Rate will be calculated on per ml basis.  | 108.00    | -         | 200,000   |                 | 1,930   | 201,930     | 109,042               |
| 7  | Atropine (Sulfate) 1mg/ml Injection                   | Atropine (Sulfate) injection 1mg/ml, Injection of 1ml ampoule, pack of 100 or less, packed in carton/box with leaflet   | 8.00      | -         | 200,000   |                 | 4,530   | 204,530     | 8,181                 |
| 8  | Beclomethasone Dipropionate 800mcg Nebulizer Solution | Beclomethasone (Dipropionate) 800mcg, suspension for aerosol therapy on single dose vial, pack of 10 or less, packed in carton with leaflet   | 72.00     | -         | 200,000   |                 | 31,700  | 231,700     | 83,412                |
| 9  | Bupivacaine HCl 0.75% Spinal Injection                | Bupivacaine (hydrochloride) (spinal) Injection 0.75% , glass Ampoule of 2ml. Pack of 10's or less Ampoules. Packed in carton with leaflet.  | 45.00     | -         | 500,000   |                 | 13,620  | 513,620     | 115,565               |
| 10 | Calcium Gluconate 100mg/ml Injection                  | Inj. Calcium Gluconate 100mg/ml , Ampoule of 10ml, Pack of 50 or less, Packed in Carton with leaflet  | 22.00     | -         | 200,000   |                 | 4,800   | 204,800     | 22,528                |
| 11 | Captopril 25mg Tab/ Cap                               | Captopril 25 mg Tablet, Blister/Al strip Packing of 30s or less in carton with leaflet.   | 13.60     | 1,703,648 | 1,000,000 |                 | 40,500  | 2,744,148   | 186,602               |
| 12 | Cefoperazone + Sulbactam 2G Injection                 | Cefoperazone+Salbactam 1gm+1gm Injection. Glass vial, individually packed in carton with solvent and leaflet  | 170.00    | 266,204   | 150,000   |                 | 9,900   | 426,104     | 362,188               |
| 13 | Ceftriaxone (Sodium) 1G Injection                     | Ceftriaxone (as sodium) I.V 1g Injection. Glass vial, individually packed in carton with water for injection 10ml and leaflet.  | 78.60     | 5,831,729 | 3,000,000 |                 | 103,000 | 8,934,729   | 3,511,349             |
| 14 | Cefotaxime 250mg Injection                            | Cefotaxime I.V 250mg injection as Cefotaxime sodium, glass vial , individually packed in carton with water for injection (min. 2ml) and leaflet.  | 59.00     | 891,171   | 800,000   |                 | 35,500  | 1,726,671   | 509,368               |
| 15 | Ciprofloxacin HCl 200mg/100ml Infusion                | Ciprofloxacin 200mg/100ml Infusion. Bottle of 100ml. in case of Poly pack, individuale bottle must be packed in outer polythene packing. (In case of poly pack the firm shall submit Undertaking on Rs. 300 legally notarized Judicial Stamp Paper to the effect that material used in manufacturing of poly pack is of pharmaceutical grade and free from DEHP or other hazardous plasticizer and source is not re-used/crushed material. The firm shall also provide trail (GD & Invoices from January 2023 onward) of pharmaceutical grade material used in poly pack. Moreover, the firm shall submit certificate from manufacturer of poly pack material that material is of pharmaceutical grade and free from DEHP or other hazardous plasticizer and source is not re-used/crushed material). | 134.00    | 400,839   | 200,000   |                 | 12,600  | 613,439     | 411,004               |
| 16 | Desferioxamine 500mg Injection                        | Desferioxamine 500mg Injection, Pack of 10 Amp or less, packed in carton.   | 150.00    |           | 5,000     |                 | 2,200   | 7,200       | 5,400                 |
| 17 | Dexamethasone 4mg/ml Injection                        | Dexamethasone 4mg/ml Injection. Vial/Amp of 1ml, Pack of 100 or less, packed in carton with leaflet   | 7.25      | 4,334,038 | 3,000,000 |                 | 118,000 | 7,452,038   | 270,136               |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr | Generic Name                                      | Specifications   | Est. Rate | DHAs       | DGHS      | Clinic on Wheel | PHFMC   | Grand Total | Value of Bid Security |
|----|---|--|-----------|------------|-----------|-----------------|---------|-------------|-----------------------|
| 18 | Dextrose + Saline (1000ml) Infusion               | Dextrose+Saline (1000ml) Infusion 5%w/v +0.9%w/v, Bottle of 1000ml individually packed in polythene sealed bag, pack of 20 bottles packed in master carton. (Undertaking on Rs. 300 legally notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade) | 85.05     | 143,367    | -         |                 | 8,850   | 152,217     | 64,730                |
| 19 | Dextrose 10% (1000ml) Infusion                    | Dextrose in Water 10% Infusion, Bottle of 1000 ml individually packed in polythene sealed bag, Pack of 20 bottles or less packed in master carton. (Undertaking on Rs. 300 legally notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade).         | 96.59     | 148,189    | -         |                 | 6,600   | 154,789     | 74,755                |
| 20 | Dextrose 25% Injection                            | Dextrose 25% Infusion , Ampoule of 20/25 ml, pack of 100 ampoule packed in master carton. (Undertaking on Rs. 300 legally notarized Judicial Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade)-Rate will be calculated on per ml basis                  | 21.00     | 498,806    | -         |                 | 10,000  | 508,806     | 53,425                |
| 21 | Dextrose 5% (1000ml) Infusion                     | Dextrose Infusion 5% Infusion of 1000ml individually packed in polythene sealed bag, pack of 20 bottles packed in master carton. (Undertaking on Rs. 300 legally notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade)                            | 84.95     | 325,665    | -         |                 | 6,400   | 332,065     | 141,045               |
| 22 | Diazepam 10mg Injection                           | Diazepam 5mg/ml Injection, ampoule of 2ml, Box/carton of 100 or less with leaflet.   | 36.80     | -          | 500,000   |                 | 3,380   | 503,380     | 92,622                |
| 23 | Diclofenac (Sodium) 75mg Injection                | Diclofenac Sodium 75mg/3ml Injection. Ampoule of 3ml, pack of 100's or less, packed in carton with leaflet   | 8.95      | 10,800,324 | 3,000,000 |                 | 452,000 | 14,252,324  | 637,792               |
| 24 | Dimenhydrinate 50mg/ml Injection                  | Dimenhydrinate 50mg/ml injection, ampoule of 1ml, pack of 50 or less packed in carton with leaflet   | 8.89      | 1,787,361  | 1,000,000 |                 | 66,000  | 2,853,361   | 126,832               |
| 25 | Dobutamine HCl 250mg Injection                    | Dobutamine (hydrochloride) Injection 250mg, Vial / ampoule of 20ml or less, Pack of 50 or less, packed in carton with leaflet.   | 350.00    | 48,486     | -         |                 | 900     | 49,386      | 86,426                |
| 26 | Dopamine HCl 200mg/5ml Injection                  | Dopamine 200mg/5ml Injection, Vial / ampoule of 5ml, Pack of 50 or less, packed in carton with leaflet   | 70.00     | 85,705     | -         |                 | 960     | 86,665      | 30,333                |
| 27 | Drotaverine 40mg/2ml Injection                    | Drotaverine 40mg Injection, 2ml, pack of 100 or less with leaflet.   | 9.95      | 3,743,059  | 2,500,000 |                 | 187,000 | 6,430,059   | 319,895               |
| 28 | Furosemide 20mg/2ml Injection                     | Furosemide 20mg/2ml Injection, Ampoule of 2ml, Pack of 100 or less, packed in carton with leaflet  | 11.00     | 2,319,029  | -         |                 | 35,300  | 2,354,329   | 129,488               |
| 29 | Glyceryl Trinitrate (Sublingual) 0.5mg Tab/ Cap   | Glyceryl Trinitrate (Sublingual) 0.5mg Tablet / capsule, pack of 600's or less, packed in carton   | 2.50      | 481,150    | 1,000,000 |                 | 23,000  | 1,504,150   | 18,802                |
| 30 | Hydrocortisone (Sodium succinate) 250mg Injection | Hydrocortisone sodium succinate 250 mg Injection, (Dry Powder) Vial, individually packed in carton with solvent & leaflet.   | 109.90    | 1,942,395  | 1,400,000 |                 | 34,000  | 3,376,395   | 1,855,329             |
| 31 | Ipratropium Bromide 250mcg Nebulizer Solution     | Ipratropium Bromide monohydrate equivalent to 0.25mg Ipratropium bromide Nebulizing Solution per ml, amp/vial of 2ml pack of 10 or less packed in carton with leaflet.   | 74.75     | -          | 200,000   |                 | 51,700  | 251,700     | 94,073                |
| 32 | Iron Sucrose 100mg Injection                      | Iron Sucrose 20mg/ml Injection. Ampule of 5ml pack of 10 or less packed with leaflet in carton. The firm will produce batch wise cold chain data from the source of origin & thermolog data from factory to ware house.  | 56.50     | 572,157    | -         |                 | 39,500  | 611,657     | 172,793               |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr | Generic Name   | Specifications  | Est. Rate | DHAs      | DGHS      | Clinic on Wheel | PHFMC   | Grand Total | Value of Bid Security |
|----|--|---|-----------|-----------|-----------|-----------------|---------|-------------|-----------------------|
| 33 | Isflurane inhalation Gas                             | Isflurane Liquid Inhalation, Bottle of 250ml/100ml, Individually packed in carton with leaflet. Rate will be calculated on per ml basis. (The company is bound to provide (with latest & high end model vaporizer, temperature & flow compensated) compatible with the anesthesia machine (as and when demanded by the end user).The company will calibrate and maintain the vaporizers free of cost.)  | 6,950.00  | 5,094     | 5,000     |                 | 190     | 10,284      | 357,378               |
| 34 | Isosorbide Dinitrate 10mg/10ml Infusion              | Inj. Isosorbide dinitrate 0.1% (10mg/10ml), Vial/ampoule of 10 ml, Pack of 10 or less, packed in carton with leaflet.   | 200.00    | 47,933    | -         |                 | 855     | 48,788      | 48,788                |
| 35 | Ketorolac tromethamine 30mg Injection                | Ketorolac tromethamine 30mg Injection. Vial/Amp of 3ml or less, Pack of 10 or less, packed in carton with leaflet.  | 15.15     | 136,039   | -         |                 | 24,100  | 160,139     | 12,131                |
| 36 | Lignocaine (hydrochloride) 2% Gel                    | Lignocaine Hydrochloride 2% gel. Sealed tube of 30gm or less, Individually Packed in carton with/without leaflet.   | 54.00     | 281,521   | -         |                 | 12,300  | 293,821     | 79,332                |
| 37 | Lignocaine (hydrochloride) 2% Injection              | Inj. Lignocaine 2% ampoule of 10ml. Pack of 100 or less, packed in carton with leaflet.   | 17.55     | 1,077,638 | 300,000   |                 | 21,500  | 1,399,138   | 122,774               |
| 38 | Magnesium Sulphate 500mg/ml Injection                | Magnesium Sulphate 500mg/ml Injection, ampoule of 10ml or less, Pack of 10 or less, packed in carton with leaflet. Rate will be calculated on per ml basis.   | 25.00     | -         | 30,000    |                 | 1,300   | 31,300      | 3,913                 |
| 39 | Mannitol (500ml) 20% w/v Infusion                    | Mannitol (500ml) Infusion 20% w/v individually packed in polythene sealed bag, pack of 20 Infusions packed in master carton. (Undertaking on Rs. 300 notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade)   | 152.00    | 65,651    | -         |                 | 455     | 66,106      | 50,241                |
| 40 | Metoclopramide (hydrochloride) 10mg Injection        | Metoclopramide 10mg/2ml Injection. Ampoule, pack of 100 or less packed in carton with leaflet   | 11.85     | 3,359,948 | 1,500,000 |                 | 82,000  | 4,941,948   | 292,810               |
| 41 | Metronidazole 500mg/100ml Infusion                   | Metronidazole 500mg/100ml Infusion, Bottle of 100ml. in case of Poly pack, individuale bottle must be packed in outer polythene packing. Hanger is mandatory for each bottle. Pack of 100 bottles or less with hangers. (In case of poly pack the firm shall submit Undertaking on Rs. 300 notarized Stamp Paper to the effect that material used in manufacturing of poly pack is of pharmaceutical grade and free from DEHP or other hazardous plasticizer and source is not re-used/crushed material. The firm shall also provide trail (GD & Invoice from January 2023 onward) of pharmaceutical grade material used in poly pack. Moreover, the firm shall submit certificate from manufacturer of poly pack material that material is of pharmaceutical grade and free from DEHP or other hazardous plasticizer and source is not re-used/crushed material. | 46.98     | 3,225,903 | 1,200,000 |                 | 79,000  | 4,504,903   | 1,058,202             |
| 42 | Misoprostol 200mcg Tab/ Cap                          | Misoprostol 200mcg Tab/Cap. Blister/ Aluminium Strip, pack of 30 or less, packed in carton with leaflet   | 10.50     | 3,078,530 | -         |                 | 114,000 | 3,192,530   | 167,608               |
| 43 | Modified Fluid Gelatin 4% / Polygeline 3.5% Infusion | Inf. Modified fluid Gelatin 4%/polygeline 3.5%. Bottle of 500ml. Individually packed & packed in master carton of 20 Bottles or less. [Undertaking to the effect that the Latex & Plastic used in manufacturing is of Pharmaceutical grade.]  | 728.00    | 72,968    | -         |                 | 1,170   | 74,138      | 269,861               |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr | Generic Name  | Specifications   | Est. Rate | DHAs      | DGHS      | Clinic on Wheel | PHFMC  | Grand Total | Value of Bid Security |
|----|---|--|-----------|-----------|-----------|-----------------|--------|-------------|-----------------------|
| 44 | Moxifloxacin 400mg Injection                        | Moxifloxacin 400mg/250ml Injection. Pack of 250ml. Individually packed in carton with leaflet. (In case of poly pack the firm shall submit Undertaking on Rs. 300 legally notarized Judicial Stamp Paper to the effect that material used in manufacturing of poly pack is of pharmaceutical grade and free from DEHP or other hazardous plasticizer and source is not re-used/crushed material. The firm shall also provide trail (GD & Invoices from January 2020 onward) of pharmaceutical grade material used in poly pack. Moreover, the firm shall submit certificate from manufacturer of poly pack material that material is of pharmaceutical grade and free from DEHP or other hazardous plasticizer and source is not reused/crushed material). | 160.00    | 105,926   | 100,000   |                 | 4,800  | 210,726     | 168,581               |
| 45 | Nalbuphine HCl 10mg/ml Injection                    | Nalbuphine Hydrochloride 10mg/ml Injection. Ampoule of 1ml, Pack of 100 or less, packed in Carton with leaflet   | 38.00     | 877,552   | 500,000   |                 | 22,000 | 1,399,552   | 265,915               |
| 46 | Neostigmine + Glycopyrrolate 2.5+0.5mg/ml Injection | Neostigmine + Glycopyrrolate 2.5+0.5mg/ml Injection, 1ml amp, pack of 100 amp or less, packed in carton with leaflet   | 99.00     | -         | 50,000    |                 | 1,500  | 51,500      | 25,493                |
| 47 | Norepinephrine 1mg/ml Injection                     | Norepinephrine 1mg/ml Injection, Ampoule of 4ml or less , Pack of 10 Ampoules or less, Packed in carton with leaflet. Rate will be calculated on per ml basis.   | 50.00     | -         | 50,000    |                 | 480    | 50,480      | 12,620                |
| 48 | Normal Saline 0.9% 1000ml Infusion                  | Normal Saline Infusion 0.9% (1000ml) individually packed in polythene sealed bag, pack of 20 infusions packed in master carton. (Undertaking on Rs. 300 notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade)   | 72.16     | 2,837,111 | 50,000    |                 | 90,000 | 2,977,111   | 1,074,142             |
| 49 | Normal Saline 100 ml Infusion                       | Normal Saline Infusion 0.9% (100ml). Pack of 200 infusions packed in master carton. (Undertaking on Rs. 300 notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade)   | 40.40     | 1,100,262 | -         |                 | 51,250 | 1,151,512   | 232,605               |
| 50 | Omeprazole 40mg Injection                           | Omeprazole Infusion/Injection (Omeprazole Sodium 42.6 mg eq. to omeprazole 40mg). Vial, Individually Packed in carton with solvent (10ml) & leaflet  | 53.00     | 2,865,276 | 1,600,000 |                 | 77,000 | 4,542,276   | 1,203,703             |
| 51 | Oxytocin 5IU/ml Injection                           | Oxytocin 5 IU/ml Injection, Glass ampoule, pack of 100 or less, packed in carton with leaflet.   | 11.85     | 2,226,578 | 2,000,000 |                 | 95,500 | 4,322,078   | 256,083               |
| 52 | Paracetamol 1g/100ml Infusion                       | Paracetamol 1 gm/ 100ml Infusion. Individually packed in glass bottle in carton with hanger and leaflet.   | 91.50     | 1,260,679 | 800,000   |                 | 50,000 | 2,110,679   | 965,636               |
| 53 | Peads Saline Solution Injection                     | Peads Soln Infusion 1/5 Normal Saline infusion (Paeds solution) 500 ml individually packed in polythene sealed bag, pack of 20 bottles packed in master carton. (Undertaking on Rs. 300 notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade)   | 63.97     | 417,635   | -         |                 | 13,800 | 431,435     | 137,995               |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr | Generic Name                                      | Specifications   | Est. Rate | DHAs      | DGHS    | Clinic on Wheel | PHFMC  | Grand Total | Value of Bid Security |
|----|---|--|-----------|-----------|---------|-----------------|--------|-------------|-----------------------|
| 54 | Pheniramine (maleate) 22.7mg or 25mg/ml Injection | Pheniramine maleate 22.7mg or 25mg/ml Injection, ampoule of 2ml, Pack of 100 or less, packed in box/carton with leaflet.   | 10.00     | 930,191   | 500,000 |                 | 22,300 | 1,452,491   | 72,625                |
| 55 | Potassium Chloride 7.46% Injection                | Potassium Chloride (KCl) Solution 7.46% in 20/25ml ampoule. pack of 200 or less packed in carton. Rate will be calculated on per ml basis.   | 14.15     | -         | 50,000  |                 | 1,320  | 51,320      | 3,631                 |
| 56 | Povidone – iodine 10% w/v Solution                | Povidone-Iodine 10% Skin Solution, Bottle of 450ml.  | 1,359.00  | 224,318   | 100,000 |                 | 11,500 | 335,818     | 2,281,882             |
| 57 | Propofol 200mg/20ml Injection                     | Inj. Propofol 200 mg, Ampoule of 20ml. Pack of 5 or less, packed in carton with leaflet.   | 446.98    | -         | 30,000  |                 | 4,430  | 34,430      | 76,948                |
| 58 | Ringer's Lactate (500ml) Infusion                 | Ringer Lactate Infusion. Bottle of 500ml individually packed in polythene sealed bag, pack of 20 infusion packed in master carton. (Undertaking on Rs. 300 notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade)  | 58.52     | 1,720,508 | -       |                 | 50,000 | 1,770,508   | 518,050               |
| 59 | Ringer's Lactate (1000ml) Infusion                | Ringer Lactate Infusion. Bottle of 1000ml individually packed in polythene sealed bag, pack of 20 infusion packed in master carton. (Undertaking on Rs. 300 notarized Stamp Paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade) | 75.00     | 2,594,341 | 50,000  |                 | 18,500 | 2,662,841   | 998,565               |
| 60 | Salbutamol (Sulfate) 5mg/ml Solution              | Salbutamol 5mg/ml Solution for nebulization. Bottle of 30ml or less, individually packed in carton with leaflet. Rate will be calculated on per ml basis.  | 48.73     | 111,175   | -       |                 | 6,840  | 118,015     | 28,754                |
| 61 | Silver Sulphadiazine 1% Cream                     | Silver Sulphadiazine 1% Cream, tube of 50 gram or less. Individually packed in carton with leaflet. Rate will be calculated on per gram basis.   | 168.00    | 132,435   | 50,000  |                 | 13,600 | 196,035     | 164,669               |
| 62 | Sodium Bicarbonate (50ml) isotonic Injection      | Sodium Bicarbonate 8.4 % / 7.5%, vial of 50ml with distilled water, pack of 100 or less  | 15.00     | -         | 50,000  |                 | 2,560  | 52,560      | 3,942                 |
| 63 | Sodium Phosphate (Enema) Solution                 | Monobasic Sodium Phosphate 16gm, Dibasic Sodium phosphate 6gm, Bottle of 135ml, Enema Bottle with Nozzle, Individually Packed in carton with leaflet.  | 146.25    | 103,976   |         |                 | 5,350  | 109,326     | 79,945                |
| 64 | Sodium Valproate 500mg Injection                  | Sodium Valproate 500mg Injection, 500mg/5ml inj, ampule, packed in carton with leaflet   | 100.00    | 49,995    | -       |                 | 600    | 50,595      | 25,298                |
| 65 | Tazobactam +Piperacillin 500mg+4g Injection       | Tazobactam 500mg + Piperacillin 4gm Injection, dry powder vial, Individually packed in carton with leaflet & solvent   | 288.00    | 147,339   | 100,000 |                 | 4,700  | 252,039     | 362,936               |
| 66 | Tramadol HCl 100mg/2ml Injection                  | Tramadol Hydrochloride 100mg /2ml Injection. Pack of 10's or less packed in carton with leaflet.   | 14.85     | 1,200,225 |         |                 | 34,000 | 1,234,225   | 91,641                |
| 67 | Tranexamic Acid 500mg/5ml Injection               | Tranexamic Acid 500mg/5ml Injection, pack of 10 ampoules or less. Packed in carton with leaflet  | 27.75     | 937,413   | 200,000 |                 | 51,000 | 1,188,413   | 164,892               |
| 68 | Vancomycin (HCl) 1g Injection                     | Vancomycin (as hydrochloride) 1000mg Injection. Dry powder vial. Individually Packed in carton with leaflet & solvent.   | 369.91    | -         | 30,000  |                 | 3,800  | 33,800      | 62,515                |
| 69 | Vitamin K1 10mg Injection                         | Inj. Vitamin K1 (Phytomenadione) 10mg, ampoule of 5ml or less, Pack of 100 or less, packed in box/carton with leaflet.   | 112.00    | 201,329   | -       |                 | 14,600 | 215,929     | 120,920               |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr | Generic Name  | Specifications  | Est. Rate | DHAs       | DGHS       | Clinic on Wheel | PHFMC     | Grand Total | Value of Bid Security |
|----|---|---|-----------|------------|------------|-----------------|-----------|-------------|-----------------------|
| 70 | Acetylsalicylic acid EC 75mg Tab/ Cap   | Aspirin 75mg. Enteric coated Tablets, Pack of 30's or less with leaflet. Blister pack.  | 1.59      | 9,620,056  | 5,000,000  |                 | 687,000   | 15,307,056  | 121,691               |
| 71 | Albendazole 200mg Tab/ Cap  | Albendazole 200mg Tab/Cap, Blister pack, pack of 2's (single dose), packed in carton with leaflet   | 13.60     | 639,169    | 500,000    |                 | 49,500    | 1,188,669   | 80,829                |
| 72 | Albendazole 200mg/5ml Syp/ Susp   | Albendazole 200mg/5ml Syp/ Susp Albendazole 200mg/5ml Syp/Susp. Bottle of 10ml packed in carton with leaflet.   | 37.74     | 638,784    | 500,000    |                 | 46,000    | 1,184,784   | 223,569               |
| 73 | Allopurinol 300mg Tab/ Cap  | Allopurinol 300mg Tab/Cap, Blister Pack, Pack of 100 or less, Packed in carton with leaflet.  | 6.21      | 799,252    | -          |                 | 103,500   | 902,752     | 28,030                |
| 74 | Alprazolam 0.5mg Tablet   | Alprazolam Tab/Cap 0.5mg, Pack of 50's or less, blister / aluminum strip , packed in carton with leaflet.   | 6.00      | -          | 2,000,000  |                 | 52,000    | 2,052,000   | 61,560                |
| 75 | Aluminium Hydroxide + Magnesium Trisilicate/Hydroxide + Simethicone Syp/ Susp | Antacid suspension containing Magnesium Hydroxides, Aluminium Hydroxide including other relevant ingredients Syp/Susp. Bottle of 120ml or less. Rate will be calculated on per ml basis             | 72.00     | 1,926,539  | 800,000    |                 | 118,000   | 2,844,539   | 1,024,034             |
| 76 | Amlodipine 5mg Tab/ Cap   | Amlodipine Besylate 5mg Tab/Cap, Pack of 30's or less, blister / aluminum strip pack, packed in carton with leaflet.  | 1.49      | 24,447,609 | 15,000,000 | 5,190,705       | 815,000   | 45,453,314  | 338,627               |
| 77 | Ammonium Chloride + others Syp/ Susp  | Ammonium Chloride+other ingredients as expectorant Syp/Susp. Bottle of 120 ml or less. Rate will be calculated on per ml basis.   | 46.57     | 2,395,584  | 1,000,000  | 462,810         | 121,000   | 3,979,394   | 926,602               |
| 78 | Amoxicillin (trihydrate) 250mg/5ml Syp/ Susp                                  | Amoxicillin 250mg/5ml Syp/Susp, Bottle of 90ml or less in powder form, individually packed in carton with measuring spoon/measuring cup and leaflet. Rate will be calculated on per ml basis.       | 128.78    | 2,653,215  | 1,200,000  | 3,572,988       | 75,500    | 7,501,703   | 4,830,346             |
| 79 | Amoxicillin (trihydrate) 500mg Tab/ Cap                                       | Amoxicillin 500mg Tab/Cap, Blister / Aluminum strip pack, pack of 100 or less capsules, packed in carton with leaflet   | 10.97     | 25,174,581 | 20,000,000 | 90,927,594      | 352,000   | 136,454,175 | 7,484,511             |
| 80 | Amoxicillin + Clavulanic Acid 312mg/5ml Syp/ Susp                             | Amoxicillin 250mg + Clavulanic Acid 62.5mg per 5ml Syp/Susp, Bottle of 90ml or less. Individually packed in carton with measuring cup / spoon and leaflet. Rate will be calculated on per ml basis. | 263.00    | 1,172,916  | 1,000,000  |                 | 76,000    | 2,248,916   | 2,957,324             |
| 81 | Amoxicillin + Clavulanic Acid 625mg Tab/ Cap                                  | Amoxicillin (as Trihydrate) 500mg +Clavulanic acid (as potassium) 125mg Tab/Cap. Blister/Bottle/Aluminum strip pack. Pack of 12 or less, packed in carton with leaflet.                             | 25.28     | 13,299,750 | 8,000,000  |                 | 970,000   | 22,269,750  | 2,814,896             |
| 82 | Atenolol 50mg Tab/ Cap  | Atenolol 50mg Tab/Cap, Pack of 30 or less, Blister Packing, Packed in carton with leaflet.  | 2.06      | 6,390,167  | 8,000,000  | 3,280,017       | 237,000   | 17,907,184  | 184,444               |
| 83 | Atorvastatin 20mg Tab/ Cap  | Atorvastatin 20mg Tab/Cap. Blister/Al strip Packing. Pack of 30's or less with leaflet.   | 2.73      | 10,478,455 | 15,000,000 |                 | 1,045,000 | 26,523,455  | 362,045               |
| 84 | Azithromycin 500mg Tab/ Cap   | Azithromycin (as dihydrate) 500mg Capsules/Tablets, Blister pack, Pack of 10 or less. Packed in carton with leaflet.  | 28.17     | 4,506,687  | 3,000,000  |                 | 530,000   | 8,036,687   | 1,131,967             |
| 85 | Betamethasone + Gentamycin Cream  | Betamethasone + Gentamycin Cream, tube of 30 gram or less, packed in cartoon  | 55.00     | 410,612    | -          |                 | 36,600    | 447,212     | 122,983               |
| 86 | Carbamazepine 200mg Tab/ Cap  | Carbamazepine 200mg Tablets, pack of 100 or less, packed in carton with leaflet   | 4.76      | -          | 2,000,000  |                 | 28,500    | 2,028,500   | 48,278                |
| 87 | Carvedilol 6.25mg Tab/ Cap  | Carvedilol 6.25mg Tab/Cap, Pack of 30's or less, blister / aluminum strip, packed in carton with leaflet.   | 6.37      | 1,075,032  | 2,000,000  |                 | 64,000    | 3,139,032   | 99,978                |
| 88 | Cefixime 200mg/5ml Syp/ Susp  | Cefixime 200mg/5ml Syp/Susp. Bottle of 30ml. Packed in carton with leaflet & measuring spoon/cup.   | 141.50    | 1,288,886  | 400,000    | 38,214          | 81,000    | 1,808,100   | 1,279,230             |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr  | Generic Name                                       | Specifications  | Est. Rate | DHAs       | DGHS       | Clinic on Wheel | PHFMC     | Grand Total | Value of Bid Security |
|-----|--|---|-----------|------------|------------|-----------------|-----------|-------------|-----------------------|
| 89  | Cefixime 400mg Tab/ Cap                            | Cefixime 400 mg Tab/Cap. Blister/ Alu strip Pack of 10 or less with leaflet   | 29.98     | 9,893,168  | 3,000,000  |                 | 437,000   | 13,330,168  | 1,998,192             |
| 90  | Cetirizine 10mg Tab/ Cap                           | Cetirizine Tab/Cap (as Hydrochloride/ dihydrochloride) 10mg Blister/strip pack of 30 or less. Packed in carton with leaflet.  | 1.05      | 28,675,614 | 20,000,000 | 67,978,089      | 860,000   | 117,513,703 | 616,947               |
| 91  | Cetirizine 5mg/5ml Syrup/Susp                      | Cetirizine 5mg/5ml Syp/Susp/liquid/solution, bottle of 60ml, packed in carton with leaflet.   | 41.88     | 1,943,914  | 500,000    | 566,838         | 100,000   | 3,110,752   | 651,391               |
| 92  | Ciprofloxacin + Dexamethasone 0.3% + 0.1% E/Drop   | Ciprofloxacin + Dexamethasone Ear drops, Bottle of 10ml or less, Individually packed in carton with leaflet. Rate will be calculated on per ml basis  | 90.00     | 209,086    | -          |                 | 10,400    | 219,486     | 98,769                |
| 93  | Ciprofloxacin HCl 500mg Tab/ Cap                   | Cap/Tab. Ciprofloxacin 500mg. blister/Aluminium strip pack. Pack of 10's, packed in carton with leaflet.  | 7.10      | 23,481,270 | 20,000,000 | 30,719,643      | 575,000   | 74,775,913  | 2,654,545             |
| 94  | Clopidogrel 75mg Tab/ Cap                          | Clopidogrel 75mg Tab/Cap. Blister/Aluminium strip Packing. Pack of 30's or less. Packed in carton with leaflet.   | 3.85      | 11,540,116 | 20,000,000 |                 | 456,000   | 31,996,116  | 615,925               |
| 95  | Clotrimazole 10%/w/w Vaginal Cream with applicator | 10%/w/w Vaginal Cream with applicator Clotrimazole 10% Vaginal Cream, Tube of 5gm, individually packed in carton with applicator & leaflet.   | 62.00     | 259,097    | 100,000    |                 | 56,200    | 415,297     | 128,742               |
| 96  | Co-trimoxazole (80/400mg) Syp/ Susp                | Sulphamethoxazole 400mg + Trimethoprim 80mg (Co-trimoxazole)/5ml Syp/Susp. Bottles of 90ml or less. Individually packed in carton with/without measuring cup /spoon and leaflet. Rate will be calculated on per ml basis. | 66.53     | 566,260    | 500,000    |                 | 34,000    | 1,100,260   | 366,001               |
| 97  | Diclofenac (Sodium) 50mg Tab/ Cap                  | Diclofenac Sodium 50mg Capsule/Tablet. Blister packing, packed in carton of 100's or less with leaflet  | 1.48      | 59,269,219 | 45,000,000 | 77,637,684      | 1,860,000 | 183,766,903 | 1,359,875             |
| 98  | Digoxin 250mcg Tab/ Cap                            | Digoxin 250 mcg Tablet, Bottle of 100 or less, packed in carton with leaflet  | 1.50      | 51,957     | -          |                 | 13,200    | 65,157      | 489                   |
| 99  | Dimenhydrinate 12.5mg/4ml Syp/ Susp                | Dimenhydrinate 12.5mg/4ml Syp/Susp. Bottle of 60ml.   | 70.73     | 710,414    | 500,000    |                 | 32,500    | 1,242,914   | 439,557               |
| 100 | Dimenhydrinate 50mg Tab/ Cap                       | Dimenhydrinate 50mg Tab/Cap, blister pack, pack of 100 or less packed in carton with leaflet,   | 2.69      | 5,168,527  | 4,000,000  | 849,195         | 224,000   | 10,241,722  | 137,751               |
| 101 | Domperidone 5mg/5ml Syp/ Susp                      | Domperidone 5mg/5ml Syrup/Susp. Bottle of 120ml or less. Individually packed in carton with leaflet. Rate will be calculated on per ml basis.   | 48.50     | 849,666    | -          |                 | 85,000    | 934,666     | 226,657               |
| 102 | Doxycycline (hyclate) 100mg Tablet                 | Doxycycline 100mg (as Hyclate) Tab/Cap, Blister Pack. Pack of 120's or less, packed in carton without leaflet. The instructions for uses/side effects etc. should be printed on the outer carton                          | 3.78      | 8,693,736  | -          |                 | 340,000   | 9,033,736   | 170,738               |
| 103 | Drotaverine 40mg Tab/ Cap                          | Drotaverine HCl 40 mg Tab/Cap, Blister/Aluminium strip pack of 100 or less, packed in a carton with leaflet.  | 2.92      | 9,065,788  | 8,000,000  |                 | 460,000   | 17,525,788  | 255,877               |
| 104 | Empagliflozin 10mg Tab/ Cap                        | Empagliflozin 10mg Tab/Cap, Blister/ Aluminium strip, Pack of 30 or less with leaflet in carton   | 4.98      | -          | 12,000,000 |                 | 844,000   | 12,844,000  | 319,816               |
| 105 | Escitalopram 10mg Tab/ Cap                         | Escitalopram 10mg Tab/Cap. Blister/Aluminium strip Pack. Pack of 30 or less. Packed in carton with leaflet.   | 2.93      | 1,800,521  | 1,500,000  |                 | 638,000   | 3,938,521   | 57,699                |
| 106 | Ferrous salt + Folic Acid Tab/ Cap                 | Ferrous Salt + Folic Acid Cap/Tab, Blister/bottle pack, pack of 100 or less, packed in carton with leaflet  | 0.77      | 52,269,417 | 30,000,000 | 273,738,123     | 3,150,000 | 359,157,540 | 1,382,757             |
| 107 | Fluconazole 150mg Tab/ Cap                         | Fluconazole 150 mg Tab/Cap. Blister/Aluminium strip pack of 4 or less. Packed in carton with leaflet.   | 39.51     | 264,234    |            |                 | 38,000    | 302,234     | 59,706                |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr  | Generic Name   | Specifications  | Est. Rate | DHAs       | DGHS       | Clinic on Wheel | PHFMC     | Grand Total | Value of Bid Security |
|-----|--|---|-----------|------------|------------|-----------------|-----------|-------------|-----------------------|
| 108 | Furosemide 40mg Tab/ Cap   | Furosemide 40mg Tablets. Pack of 200 or less. Packed in carton with leaflet.  | 3.24      | -          | 3,000,000  |                 | 105,000   | 3,105,000   | 50,301                |
| 109 | Glimepiride 2mg Tab/ Cap   | Glimepiride 2 mg Tab/Cap. Pack of 100's or less. Packed in carton with leaflet.   | 1.37      | 14,499,833 | 20,000,000 |                 | 910,000   | 35,409,833  | 242,557               |
| 110 | Glyceryl Trinitrate (S.R) 2.6mg Tab/ Cap                         | Glyceryl Trinitrate 2.6mg Tablets, SR, pack of 100 or less, packed in carton/bottle.  | 2.95      | 2,217,810  | 5,000,000  |                 | 33,000    | 7,250,810   | 106,949               |
| 111 | Ibuprofen 100mg/5ml Syp/ Susp                                    | Ibuprofen 100mg/5ml Syp/Susp. Bottle of 120ml or less. Individually packed in carton. Rate will be calculated on per ml basis   | 67.30     | 2,974,180  | 1,000,000  |                 | 138,000   | 4,112,180   | 1,383,749             |
| 112 | Ibuprofen 200mg Tab/ Cap   | Ibuprofen 200mg Tablets (film/sugar coated). Blister Packing. Pack of 250's or less without leaflet. The instructions for uses/side effects etc. should be printed on the outer carton  | 3.60      | 5,733,421  | 10,000,000 |                 | 370,000   | 16,103,421  | 289,862               |
| 113 | Lisinopril 10mg Tab/ Cap   | Lisinopril 10mg Tab/Cap, Blister/ Aluminium strip, Pack of 30 or less with leaflet  | 3.83      | 3,920,641  | 10,000,000 |                 | 351,000   | 14,271,641  | 273,302               |
| 114 | Losartan Potassium 50mg Tab/ Cap                                 | Losartan Potassium 50 mg Tab/Cap, Blister/Aluminium strip packing of 20 or less packed in carton with leaflet   | 2.90      | 6,443,488  | 10,000,000 |                 | 490,000   | 16,933,488  | 245,536               |
| 115 | Metformin (hydrochloride) 500mg Tab/ Cap                         | Metformin 500mg Tab/Cap, Blister pack. Pack of 100 or less. Packed in carton with leaflet   | 2.39      | 30,854,845 | 50,000,000 | 6,496,344       | 1,410,000 | 88,761,189  | 1,060,696             |
| 116 | Methyldopa 250mg Tab/ Cap  | Methyldopa 250mg Tablet, Bottle / blister pack of 100 or less, Packed in carton with leaflet  | 12.50     | 692,281    | 1,000,000  |                 | 56,000    | 1,748,281   | 109,268               |
| 117 | Metronidazole (benzoate) 200mg/5ml Syp/ Susp                     | Metronidazole (as benzoate) 200mg/5ml Syp/Susp, Bottle of 120ml or less. Individually packed in carton with leaflet. Rate will be calculated on per ml basis.   | 76.00     | 1,570,498  | 600,000    | 2,751,393       | 86,000    | 5,007,891   | 1,902,998             |
| 118 | Metronidazole 400mg Tab/ Cap                                     | Metronidazole 400mg Tab/Cap, blister/ Aluminium Strip, pack of 200's or less, packed in carton with leaflet   | 2.49      | 25,944,529 | 20,000,000 | 17,196,207      | 790,000   | 63,930,736  | 795,938               |
| 119 | Montelukast 10mg Tab/ Cap  | Montelukast as sodium 10mg Tab/Cap. Blister / Aluminium strip, pack of 30 or less. Packed in carton with leaflet  | 3.07      | 10,059,806 | 3,000,000  |                 | 650,000   | 13,709,806  | 210,446               |
| 120 | Moxifloxacin 0.5% Eye Drop                                       | Eye Drops Moxifloxacin 0.5%, Bottle of 5ml, Individually packed in carton with leaflet.   | 60.00     | 143,827    |            |                 | 4,700     | 148,527     | 44,558                |
| 121 | Multivitamin (Vitamin A, D, E + B Complex etc.) Tablet / Capsule | Multivitamins Tab/Cap, (Nicotinic Acid, Vitamin B2, Vitamin B1, Cyanocobalamin, Folic Acid/Folic Acid, Pyridoxine). Bottle / Blister Pack of 100's or less.   | 5.93      | 8,284,965  | -          | 64,772,376      | 1,640,000 | 74,697,341  | 2,214,776             |
| 122 | Nystatin 100,000 IU/ml Solution                                  | Nystatin 100,000 IU/ml Drops with dropper. Bottle of 60ml or less, individually packed in carton with dropper and leaflet. Rate will be calculated on per ml basis  | 130.00    | 165,180    | -          |                 | 23,500    | 188,680     | 122,642               |
| 123 | Omeprazole 20mg Tab/ Cap   | Omeprazole 20mg Tab/Cap, blister /Aluminium strip pack of 21's or less, packed in carton with leaflet.  | 1.70      | 54,158,304 | 40,000,000 | 86,104,164      | 2,460,000 | 182,722,468 | 1,553,141             |
| 124 | ORS (WHO RECOMMENDED) Powder                                     | ORS (Oral Rehydration Salt) WHO formulation (Low Osmolarity). Each sachet contains Sodium Chloride 2.60 gm + Tri-/Sodium Citrate 2.90 gm + Potassium Chloride 1.5 gm + Dextrose Anhydrous 13.50 gm. Pack of 100 or less.                                | 19.10     | 2,185,138  | 2,000,000  | 11,039,541      | 152,000   | 15,376,679  | 1,468,473             |
| 125 | Paracetamol 120mg/5ml Syp/ Susp                                  | Paracetamol 120mg/5ml or 160mg/5ml Syp/Susp/Liquid, bottle of 120ml or less, individually packed in carton without leaflet. The Instructions for uses/sides effects etc. should be printed on the outer carton. Rate will be calculated on per ml basis | 58.20     | 3,912,906  | 4,500,000  | 7,058,937       | 204,000   | 15,675,843  | 4,561,670             |
| 126 | Paracetamol 500mg Tab/ Cap                                       | Paracetamol 500 mg Tab/Cap, blister packing, packed in carton of 10x20's or less.   | 1.49      | 99,368,008 | 80,000,000 | 133,068,915     | 3,590,000 | 316,026,923 | 2,354,401             |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr  | Generic Name   | Specifications   | Est. Rate | DHAs      | DGHS       | Clinic on Wheel | PHFMC   | Grand Total | Value of Bid Security |
|-----|--|--|-----------|-----------|------------|-----------------|---------|-------------|-----------------------|
| 127 | Permethrin 5% lotion                                   | Lotion Permethrin 5%, Bottle of 60ml or less. Individually packed in carton. The instructions for uses/side effects etc. should be printed on the outer carton. Rate will be calculated on per ml basis  | 97.50     | 893,332   | 700,000    | 1,356,591       | 55,000  | 3,004,923   | 1,464,900             |
| 128 | Polymyxin B (Sulphate) + Bacitracin Zinc Eye Ointment  | Polymyxin B Sulphate 10,000 Units + Zinc Bacitracin 500 Units per gm eye ointment, Tube of 6gm or less, Individually packed in carton with/without* leaflet.*The instructions for uses/side effects etc. should be printed on the outer carton. Rate will be calculated on per gm basis. | 68.00     | 264,983   | 500,000    |                 | 31,000  | 795,983     | 270,634               |
| 129 | Polymyxin B (Sulphate) + Bacitracin Zinc skin Ointment | Polymyxin B Sulphate 10,000 Units + Zinc Bacitracin 500 Units per gm Skin Ointment, Tube of 20gm or less, Individually packed in carton. The instructions for uses/side effects etc. should be printed on the outer carton. Rate will be calculated on per gm basis.                     | 139.00    | 572,781   | 1,000,000  | 152,856         | 41,000  | 1,766,637   | 1,227,813             |
| 130 | Prednisolone 5mg Tab/ Cap                              | Prednisolone 5mg Tab/Cap, bottle/ blister pack, pack of 1000 or less.  | 2.32      | 2,507,307 | 2,000,000  |                 | 72,000  | 4,579,307   | 53,120                |
| 131 | Salbutamol (Sulfate) 2mg/5ml Syp/ Susp                 | Salbutamol 2mg/5ml Syp/Susp. Individually packed in carton. Bottle of 120ml or less. Rate will be calculated on per ml basis.  | 36.00     | 627,529   | 200,000    |                 | 31,250  | 858,779     | 154,580               |
| 132 | Sitagliptin 50mg Tab/ Cap                              | Sitagliptin 50mg Tab/Cap, Blister/Aluminium strip, Pack of 30 or less with leaflet   | 5.78      | 3,754,482 | 12,000,000 |                 | 360,000 | 16,114,482  | 465,709               |
| 133 | Sodium Picosulfate 5mg Tab/ Cap                        | Sodium Picosulphate Tablet, Pack of 100's or less, Blister Packing, packed in carton with leaflet.   | 2.98      | 1,360,912 | 5,000,000  |                 | 73,500  | 6,434,412   | 95,873                |
| 134 | Tamsulosin HCl 0.4mg Tab/ Cap                          | Tamsulosin HCl 0.4mg Tab/Cap, Blister Packing of 20 or less, packed in carton with leaflet   | 8.43      | 600,124   | 1,000,000  |                 | 66,000  | 1,666,124   | 70,227                |
| 135 | Tobramycin + Dexamethasone 0.3% E/Drop                 | Eye Drops Tobramycin 0.3% with Dexamethaxone 0.1%, Bottle of 5ml. Individually packed in carton with leaflet   | 70.00     | 421,814   | 400,000    |                 | 12,700  | 834,514     | 292,080               |
| 136 | Tranexamic Acid 500mg Tab/ Cap                         | Tranexamic Acid 500mg Tab/Cap, Blister/Aluminium strip packing, pack of 20 or less packed in carton with leaflet.  | 17.37     | 1,444,971 | 500,000    |                 | 179,000 | 2,123,971   | 184,467               |
| 137 | Zinc Sulphate 20mg/5ml Syp/ Susp                       | Zinc Sulphate Monohydrate Syp/Susp (equivalent to elemental Zinc 20 mg/5 ml in liquid dosage form. Bottle of 60ml.   | 41.90     | 983,980   | 500,000    |                 | 78,000  | 1,561,980   | 327,235               |
| 138 | Aminophylline 25mg/ml Injection                        | Aminophylline 25mg/ml, Injection of 10ml ampoule, pack of 100 or less, packed in carton with leaflet.  | 10.00     | 53,125    | -          |                 | 1,050   | 54,175      | 2,709                 |
| 139 | Amiodarone HCl 200mg Tab/ Cap                          | Tab. Amiodarone (as Hydrochloride) 200mg , Pack of 50's or less, Blister Packing, packed in carton with leaflet.   | 25.00     | 30,429    | 1,000,000  |                 | 440     | 1,030,869   | 128,859               |
| 140 | Artemether + Lumefantrine 15+90mg Syp/ Susp            | Artemether 15mg + Lumefantrine 90mg Syp/Susp. Bottle of 30ml. Packed in carton with leaflet & spoon.   | 60.80     | 67,083    | 20,000     |                 | 13,000  | 100,083     | 30,425                |
| 141 | Artemether + Lumefantrine 20+120mg Tab/ Cap            | Artemether + Lumefantrine 20/120 mg Tab/Cap. Pack of 16 Tablets in blister pack with leaflet inside.   | 12.50     | 276,120   | 100,000    |                 | 30,000  | 406,120     | 25,382                |
| 142 | Bupivacaine HCl 0.50% Injection                        | Bupivacaine (hydrochloride) Injection 0.50% Ampoule of 10mL. Pack of 10s Ampoules or less . Packed in carton with leaflet  | 28.80     | -         | 50,000     |                 | 1,700   | 51,700      | 7,445                 |
| 143 | Charcoal (Activated) 250mg Powder                      | Activated Charcoal 250mg / 260mg, Pack of 100 or less, Bottle/ Blister / Aluminium strip pack.   | 80.00     | -         | 10,000     |                 | 380     | 10,380      | 4,152                 |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr  | Generic Name                                 | Specifications  | Est. Rate | DHAs       | DGHS       | Clinic on Wheel | PHFMC   | Grand Total | Value of Bid Security |
|-----|--|---|-----------|------------|------------|-----------------|---------|-------------|-----------------------|
| 144 | Chlorpheniramine maleate 2mg/5ml Syrup       | Chlorpheniramine maleate 2mg / 5ml Syp/Susp, bottle of 120ml or less, packed in carton. Rate will be calculated on per ml basis             | 49.00     | 844,169    | 500,000    |                 | 22,500  | 1,366,669   | 334,834               |
| 145 | Chlorpheniramine maleate 4mg Tablet          | Chlorpheniramine Maleate 4mg Tab, Blister Pack, Pack of 1000's Tablets or less.   | 1.00      | 25,137,275 | 40,000,000 |                 | 128,000 | 65,265,275  | 326,326               |
| 146 | Co-trimoxazole (160/800mg) Tab/ Cap          | Sulphamethoxazole 800mg + Trimethoprim 160 mg (Co-trimoxazole) Tab/Cap, Blister pack, pack of 400 or less,packed in carton.                 | 7.75      | 2,628,613  | -          |                 | 24,000  | 2,652,613   | 102,789               |
| 147 | Flurbiprofen 100mg Tab/ Cap                  | Flurbiprofen 100mg Tab/Cap, Blister/ Aluminium strip, Pack of 30 or less with leaflet   | 4.90      | -          | 1,000,000  |                 | 188,000 | 1,188,000   | 29,106                |
| 148 | Hydralazine HCl 20mg/ml Injection            | Hydralazine HCl 20mg/ml Injection, pack of 100's or less, packed in carton with leaflet   | 35.00     | -          | 50,000     |                 | 6,015   | 56,015      | 9,803                 |
| 149 | Meropenem 500mg Injection                    | Meropenem 500mg dry powder vial, individually packed in carton with leaflet & Solvent   | 238.00    | 111,464    |            |                 | 8,150   | 119,614     | 142,340               |
| 150 | Ondansetron 8mg Injection                    | Ondansetron 8mg Injection, Ampoule of 4ml or less, Pack of 10 or less, packed in carton with leaflet  | 22.00     | 198,107    | -          |                 | 48,100  | 246,207     | 27,083                |
| 151 | Paracetamol 150mg/ml Injection               | Paracetamol 150mg/ml Injection , ampoule of 2ml , pack of 100's or less, packed in carton with leaflet.                                     | 15.00     | 486,220    | 1,500,000  |                 | 34,500  | 2,020,720   | 151,554               |
| 152 | Pralidoxime 200mg/10ml Injection             | Pralidoxime 200mg/10ml Injection, pack 10 or less, packed in carton with leaflet.   | 125.00    | -          | 5,000      |                 | 265     | 5,265       | 3,291                 |
| 153 | Pregabalin 75mg Capsule                      | Pregabalin 75mg Tab/Cap, Blister Packing of 30 or less, packed in carton with leaflet.  | 6.21      | 523,374    | -          |                 | 363,000 | 886,374     | 27,522                |
| 154 | Protamine Sulphate 100mg/ml Injection        | Protamine Sulphate 10mg/ml injection 5ml vial packed in carton with leaflet   | 70.00     | -          | 10,000     |                 | 355     | 10,355      | 3,624                 |
| 155 | Risperidone 2mg Tablet                       | Risperidone 2mg Tablet , Blister / Aluminium strip, pack of 30s or less, packed incarton with leaflet.                                      | 12.00     | 172,247    | -          |                 | 16,100  | 188,347     | 11,301                |
| 156 | Terbinafine HCl 250mg Tablet                 | Terbinafine 250mg Tab/Cap, Blister pack, pack of 10, packed in carton with leaflet.   | 37.40     | 259,210    | 300,000    |                 | 26,200  | 585,410     | 109,472               |
| 157 | Thyroxine 50mcg Tab/ Cap                     | Thyroxine / levothyroxine 50mcg. Bottle / Blister 100 or less, packed in carton with leaflet  | 4.00      | -          | 500,000    |                 | 20,000  | 520,000     | 10,400                |
| 158 | Tizanidine 2mg Tablet                        | Tizanidine HCl 2mg Tab/Cap, Blister Packing of 20 or less, packed in carton with leaflet  | 11.00     | -          | 1,000,000  |                 | 393,500 | 1,393,500   | 76,643                |
| 159 | Acefylline 125mg/5ml Syrup/ Suspension       | Acefylline 125mg/5ml Syp. Bottle of 125 ml or less. Rate will be calculated on per ml basis.  | 81.49     | -          |            | 392,754         |         | 392,754     | 160,028               |
| 160 | Chloramphenicol 0.5% Eye Drop                | Chloramphenicol 0.5% Eye Drops, Bottle of 15 ml or less, individually packed in carton with leaflet Rate will be calculated on per ml basis | 92.00     | -          |            | 159,225         |         | 159,225     | 73,244                |
| 161 | Ferric carboxymaltose Injection 500mg /10 ml | Ferric carboxymaltose Injection 50mg/ml, glass vial of 10ml, packed in carton with leaflet  | 1,000.00  | -          | 50,000     |                 |         | 50,000      | 250,000               |
| 162 | Iron isomaltoside 100mg/ml Injection         | Iron isomaltoside 100mg/ml Injection, Ampoule of 1ml, Pack of 10 or less, Packed in carton with leaflet                                     | 250.00    | -          | 200,000    |                 |         | 200,000     | 250,000               |
| 163 | Iohexol 350mg I/100ml Injection              | Iohexol 350mg/ml/Iopromide 370mg/ml 100ml vial, packed in carton with leaflet.  | 3,994.00  | -          | 80,000     |                 |         | 80,000      | 1,597,600             |
| 164 | Tirofiban Injection                          | Injection tirofiban hydrochloride , 12.5mg/50ml, individually packed in carton with leaflet   | 12,000.00 | -          | 12,000     |                 |         | 12,000      | 720,000               |

**ANNEXURE-MEDICINES (SPECIFICATIONS, RATE QUANTITY)**

| Sr  | Generic Name                                  | Specifications   | Est. Rate | DHAs | DGHS       | Clinic on Wheel | PHFMC | Grand Total | Value of Bid Security |
|-----|---|--|-----------|------|------------|-----------------|-------|-------------|-----------------------|
| 165 | Sofosbuvir 400mg Tab/Cap                      | Sofosbuvir 400mg Capsule/Tablet Packed in bottle/blister pack of 30 or less packed in carton with leaflet. | 84.77     | -    | 12,600,000 |                 |       | 12,600,000  | 5,340,510             |
| 166 | Daclatasvir 60mg Tab/Cap                      | Daclatasvir 60mg bottle/blister pack of 30 or less of tablet/capsule packed in carton with leaflet         | 10.61     | -    | 12,600,000 |                 |       | 12,600,000  | 668,430               |
| 167 | Tenofovir (disoproxil fumarate) 300mg Tab/Cap | Tenofovir 300mg Tab/Cap, blister/ bottle pack, Pack of 30 or less  | 16.73     | -    | 1,800,000  |                 |       | 1,800,000   | 150,570               |
| 168 | Entecavir 0.5mg Tab/Cap                       | Entecavir 0.5mg Tab/Cap, blister pack/ bottle, pack of 30 or less, packed in carton with leaflet           | 6.97      | -    | 1,800,000  |                 |       | 1,800,000   | 62,730                |
| 169 | Bisoprolol 5mg Tab/Cap                        | Bisoprolol 5mg Tab/Cap, Blister Pack of 30 or less, Packed in carton with leaflet                          | 9.95      | -    | 2,000,000  |                 |       | 2,000,000   | 99,500                |
| 170 | Rosuvastatin 10mg Tab/Cap                     | Rosuvastatin 10mg Tab/Cap, Blister Pack of 30 or less, Packed in carton with leaflet                       | 10.00     | -    | 2,000,000  |                 |       | 2,000,000   | 100,000               |
| 171 | Spironolactone + Furosemide 50mg+40mg Tab/cap | Spironolactone 50mg + Furosemide 40mg Tab/cap, Blister Pack of 30 or less, Packed in carton with leaflet.  | 5.20      | -    | 1,000,000  |                 |       | 1,000,000   | 26,000                |
| 172 | Ticagrelor 90mg Tab/Cap                       | Ticagrelor 90mg Tab/Cap, Blister Pack of 30 or less, Packed in carton with leaflet                         | 30.00     | -    | 1,000,000  |                 |       | 1,000,000   | 150,000               |
| 173 | Valsartan 160mg Tab/Cap                       | Valsartan 160mg Tab/Cap, Blister Pack of 30 or less, Packed in carton with leaflet                         | 9.00      | -    | 1,500,000  |                 |       | 1,500,000   | 67,500                |
| 174 | Diltiazem 60mg Tab/Cap                        | Diltiazem 60mg Tab/Cap, Blister Pack of 30 or less, Packed in carton with leaflet                          | 12.45     | -    | 1,000,000  |                 |       | 1,000,000   | 62,250                |
| 175 | Adenosine 6mg/2ml injection                   | Adenosine 6mg/2ml injection, Pack of 10's, packed in carton with leaflet                                   | 60.00     | -    | 10,000     |                 |       | 10,000      | 3,000                 |
| 176 | Pyridoxine 50mg Tab/Cap                       | Pyridoxine 50mg Tab/Cap, Blister Pack of 30 or less, Packed in carton with leaflet                         | 2.09      | -    | 20,000,000 |                 |       | 20,000,000  | 209,000               |
| 177 | Verapamil 2.5mg/ml Injection                  | Verapamil 2.5mg/ml Injection, Pack of 10 injection, packed in carton with leaflet                          | 10.00     | -    | 20,000     |                 |       | 20,000      | 1,000                 |
| 178 | Digoxin 500mcg Injection                      | Digoxin 500mcg Injection, Pack of 10's or less, packed in carton with leaflet.                             | 15.00     | -    | 10,000     |                 |       | 10,000      | 750                   |